1
|
Du P, Huang L, Fang Y, Zhao F, Li Q, Ma X, Li R, Chen Q, Shen H, Wang Q, Li H, Gao GF. Broad-spectrum Delta-BA.2 tandem-fused heterodimer mRNA vaccine delivered by lipopolyplex. PLoS Pathog 2024; 20:e1012116. [PMID: 38557908 PMCID: PMC11008869 DOI: 10.1371/journal.ppat.1012116] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2023] [Revised: 04/11/2024] [Accepted: 03/12/2024] [Indexed: 04/04/2024] Open
Abstract
Since the beginning of the coronavirus disease 2019 (COVID-19) pandemic, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, continues to mutate and generates new variants with increasingly severe immune escape, urging the upgrade of COVID-19 vaccines. Here, based on a similar dimeric RBD design as our previous ZF2001 vaccine, we developed a novel broad-spectrum COVID-19 mRNA vaccine, SWIM516, with chimeric Delta-BA.2 RBD dimer delivered by lipopolyplex (LPP). Unlike the popular lipid nanoparticle (LNP), this LPP-delivered mRNA expresses only in the injection site, which avoids potential toxicity to the liver. We demonstrated the broad-spectrum humoral and cellular immunogenicity of this vaccine to Delta and Omicron sub-variants in naïve mice and as booster shots. When challenged with Delta or Omicron live virus, vaccinated human angiotensin-converting enzyme (hACE2) transgenic mice and rhesus macaques were both protected, displaying significantly reduced viral loads and markedly relieved pathological damages. We believe the SWIM516 vaccine qualifies as a candidate for the next-generation broad-spectrum COVID-19 vaccine.
Collapse
Affiliation(s)
- Pei Du
- CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), Beijing, China
| | - Lei Huang
- Stemirna Therapeutics, Shanghai, China
| | - Yi Fang
- Stemirna Therapeutics, Shanghai, China
| | | | | | - Xuehui Ma
- CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), Beijing, China
| | - Ruiqi Li
- CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), Beijing, China
- Medical School, University of Chinese Academy of Sciences, Beijing, China
| | - Qian Chen
- CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), Beijing, China
- Faculty of Health Sciences, University of Macau, Macau, China
| | | | - Qihui Wang
- CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), Beijing, China
- Medical School, University of Chinese Academy of Sciences, Beijing, China
- Faculty of Health Sciences, University of Macau, Macau, China
| | | | - George Fu Gao
- CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), Beijing, China
- Medical School, University of Chinese Academy of Sciences, Beijing, China
- Faculty of Health Sciences, University of Macau, Macau, China
| |
Collapse
|
2
|
Huang L, Zhao F, He M, Fang Y, Ma X, Lu S, Li E, Xiao H, Zhu H, Wang X, Tang S, Yu B, Wang J, Zhao D, Wang C, Li H, Gao Y, Peng X, Shen H. An inoculation site-retained mRNA vaccine induces robust immune responses against SARS-CoV-2 variants. J Control Release 2024; 366:479-493. [PMID: 38184234 DOI: 10.1016/j.jconrel.2024.01.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2023] [Revised: 12/20/2023] [Accepted: 01/01/2024] [Indexed: 01/08/2024]
Abstract
mRNA-based vaccines and therapeutic agents hold great promise in prevention and treatment of human diseases, yet high percentage of systemic adverse effect in clinic remains a big safety concern. One major potential cause is a high level of leakage of the locally inoculated mRNA vaccine nanoparticles into circulation. We have screened and optimized a core-shell structured lipopolyplex (LPP) formulation for mRNA with a tissue-retention property. Upon intramuscular inoculation, the mRNA-encapsulated LPP nanoparticles were preferentially taken up by the phagocytic antigen-presentation cells, and potently promoted dendritic cell maturation. We applied the new formulation to prepare a prophylactic vaccine for SARS-CoV-2, and observed potent humoral and cellular immune responses from the vaccine in both murine models and non-human primates. More importantly, the vaccine demonstrated a benign safety profile in non-human primates, with limited side effects after repeated treatment with high dosages of LPP/mRNA. Taken together, the inoculation site-retained vaccine formulation serves as a promising vehicle for mRNA vaccines and therapeutic agents.
Collapse
Affiliation(s)
- Lei Huang
- Stemirna Therapeutics, Shanghai 201206, China; Department of Material Science, Fudan University, Shanghai 200433, China
| | - Fanfan Zhao
- Stemirna Therapeutics, Shanghai 201206, China
| | - Muye He
- Stemirna Therapeutics, Shanghai 201206, China
| | - Yi Fang
- Stemirna Therapeutics, Shanghai 201206, China
| | - Xiaoping Ma
- Stemirna Therapeutics, Shanghai 201206, China
| | - Shuaiyao Lu
- Institute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Kunming 650118, China
| | - Entao Li
- Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun 130122, China
| | - Hui Xiao
- Stemirna Therapeutics, Shanghai 201206, China
| | - Hanfei Zhu
- Stemirna Therapeutics, Shanghai 201206, China
| | - Xueli Wang
- Stemirna Therapeutics, Shanghai 201206, China
| | - Siyuan Tang
- Stemirna Therapeutics, Shanghai 201206, China
| | - Bo Yu
- Stemirna Therapeutics, Shanghai 201206, China
| | - Jie Wang
- Stemirna Therapeutics, Shanghai 201206, China
| | - Dong Zhao
- Department of Material Science, Fudan University, Shanghai 200433, China
| | - Chao Wang
- Department of Material Science, Fudan University, Shanghai 200433, China
| | - Hangwen Li
- Stemirna Therapeutics, Shanghai 201206, China.
| | - Yuwei Gao
- Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun 130122, China.
| | - Xiaozhong Peng
- Institute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Kunming 650118, China.
| | - Haifa Shen
- Stemirna Therapeutics, Shanghai 201206, China.
| |
Collapse
|
3
|
Chen K, Wang T, Tong X, Song Y, Hong J, Sun Y, Zhuang Y, Shen H, Yao XI. Osteoporosis is associated with depression among older adults: a nationwide population-based study in the USA from 2005 to 2020. Public Health 2024; 226:27-31. [PMID: 37988825 DOI: 10.1016/j.puhe.2023.10.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2023] [Revised: 09/27/2023] [Accepted: 10/11/2023] [Indexed: 11/23/2023]
Abstract
OBJECTIVES The global prevalence of osteoporosis is rising, yet it is unclear whether people with osteoporosis have a higher risk of depression than those without osteoporosis. STUDY DESIGN A cross-sectional study. METHODS We used nationally representative data from the US National Health and Nutrition Examination Survey (NHANES) in 2005-2006, 2007-2008, 2009-2010, 2013-2014, and 2017-2020. The diagnosis of osteoporosis was based on the bone mineral density of the femoral neck measured by dual-energy X-ray absorptiometry. Depression was assessed by the Patient Health Questionnaire-9 (PHQ-9), with a score ≥5 as depressive symptoms and a score ≥10 as probable depression. We used logistic regression models to evaluate the association between osteoporosis and depressive symptoms and probable depression. RESULTS We included 11,603 adults (aged 50 years and older, 52.3% male) and observed 5.2% of them had osteoporosis. 31.9% of these osteoporotic people had depressive symptoms, and 10.0% had probable depression. Compared to participants without osteoporosis, those with osteoporosis were 1.73 times more likely to experience depressive symptoms (odds ratio [OR] = 1.73, 95% confidence interval [CI] 1.20-2.50) and 1.91 times more likely to experience probable depression (OR = 1.91, 95% CI 1.02-3.59), after adjusting for sex, age, race/ethnicity, education, marital status, family income, body mass index, smoking, physical activity, and alcohol abuse. Moderate-to-vigorous activities mediated the associations between osteoporosis and depression and depressive symptoms. CONCLUSIONS Osteoporosis is an independent risk factor for depression. This study highlights the need to evaluate the mental well-being of patients with osteoporosis in clinical and primary health care.
Collapse
Affiliation(s)
- K Chen
- Department of Orthopaedics, The Eighth Affiliated Hospital, Sun Yat-sen University, 3025 Shennan Road, Shenzhen 518000, PR China.
| | - T Wang
- Department of Orthopaedics, The Eighth Affiliated Hospital, Sun Yat-sen University, 3025 Shennan Road, Shenzhen 518000, PR China.
| | - X Tong
- Department of Orthopaedics, The Eighth Affiliated Hospital, Sun Yat-sen University, 3025 Shennan Road, Shenzhen 518000, PR China.
| | - Y Song
- Department of Orthopaedics, The Eighth Affiliated Hospital, Sun Yat-sen University, 3025 Shennan Road, Shenzhen 518000, PR China.
| | - J Hong
- Department of Orthopaedics, The Eighth Affiliated Hospital, Sun Yat-sen University, 3025 Shennan Road, Shenzhen 518000, PR China.
| | - Y Sun
- Department of Preventive Medicine, The University of Tennessee Health Science Center, Memphis, TN 38163, USA.
| | - Y Zhuang
- Department of Orthopaedics, The Eighth Affiliated Hospital, Sun Yat-sen University, 3025 Shennan Road, Shenzhen 518000, PR China.
| | - H Shen
- Department of Orthopaedics, The Eighth Affiliated Hospital, Sun Yat-sen University, 3025 Shennan Road, Shenzhen 518000, PR China; Department of Clinical Research, The Eighth Affiliated Hospital, Sun Yat-sen University, 3025 Shennan Road, Shenzhen 518000, PR China.
| | - X I Yao
- Department of Orthopaedics, The Eighth Affiliated Hospital, Sun Yat-sen University, 3025 Shennan Road, Shenzhen 518000, PR China; Department of Clinical Research, The Eighth Affiliated Hospital, Sun Yat-sen University, 3025 Shennan Road, Shenzhen 518000, PR China.
| |
Collapse
|
4
|
Fang Y, Li JX, Duangdany D, Li Y, Guo XL, Phamisith C, Yu B, Shen MY, Luo B, Wang YZ, Liu SJ, Zhao FF, Xu CC, Qiu XH, Yan R, Gui YZ, Pei RJ, Wang J, Shen H, Guan WX, Li HW, Mayxay M. Safety, immunogenicity, and efficacy of a modified COVID-19 mRNA vaccine, SW-BIC-213, in healthy people aged 18 years and above: a phase 3 double-blinded, randomized, parallel controlled clinical trial in Lao PDR (Laos). EClinicalMedicine 2024; 67:102372. [PMID: 38169790 PMCID: PMC10758727 DOI: 10.1016/j.eclinm.2023.102372] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/08/2023] [Revised: 11/27/2023] [Accepted: 11/28/2023] [Indexed: 01/05/2024] Open
Abstract
Background The mRNA vaccine has demonstrated significant effectiveness in protecting against SARS-CoV-2 during the pandemic, including against severe forms of the disease caused by emerging variants. In this study, we examined safety, immunogenicity, and relative efficacy of a heterologous booster of the lipopolyplex (LPP)-based mRNA vaccine (SW-BIC-213) versus a homologous booster of an inactivated vaccine (BBIBP) in Laos. Methods In this phase 3 clinical trial, which was randomized, parallel controlled and double-blinded, healthy adults aged 18 years and above were recruited from the Southern Savannakhet Provincial Hospital and Champhone District Hospital. The primary outcomes were safety and immunogenicity, with efficacy as an exploratory endpoint. Participants who were fully immunized with a two-dose inactivated vaccine for more than 6 months were assigned equally to either the SW-BIC-213 group (25 μg) or BBIBP group. The primary safety endpoint was to describe the safety profile of all participants in each group up to 6 months post-booster immunization. The primary immunogenic outcome was to demonstrate the superiority of the neutralizing antibody response, in terms of geometric mean titers (GMTs) of SW-BIC-213, compared with BBIBP 28 days after the booster dose. The exploratory efficacy endpoint aimed to assess the relative efficacy of SW-BIC-213 compared to BBIBP against virologically confirmed symptomatic COVID-19 over a 6-month period. The trial was registered with ClinicalTrials.gov (NCT05580159). Findings Between October 10, 2022, and January 13, 2023, 1200 participants were assigned to SW-BIC-213 group and 1203 participants in the BBIBP group. All adverse reactions observed during the study were tolerable, transient, and resolved spontaneously. Solicited local reactions were the main adverse reactions in both the SW-BIC-213 group (43.8%) and BBIBP group (14.8%) (p < 0.001). Heterologous boosting with SW-BIC-213 induced higher live virus neutralizing antibodies to SARS-CoV-2 wildtype and BA.5 strains with GMTs reaching 750.1 and 192.9 than homologous boosting with BBIBP with GMTs of 131.5 (p < 0.001) and 47.5 (p < 0.001) on day 29. The statistical findings revealed that, following a period of 14-day to 6-month after booster vaccination, the SW-BIC-213 group exhibited a relative vaccine efficacy (VE) of 70.1% (95% CI: 34.2-86.4) against symptomatic COVID-19 when compared to the BBIBP group. Interpretation A heterologous booster with the COVID-19 mRNA vaccine SW-BIC-213 manifests a favorable safety profile and proves highly immunogenic and efficacious in preventing symptomatic COVID-19 in individuals who have previously received two doses of inactivated vaccine. Funding Shanghai Strategic Emerging Industries Development Special Fund, Biomedical Technology Support Special Project of Shanghai "Science and Technology Innovation Action Plan", Shanghai Municipal Science and Technology Commission.
Collapse
Affiliation(s)
- Yi Fang
- Stemirna Therapeutics, Shanghai, China
| | - Jing-Xin Li
- Jiangsu Provincial Medical Innovation Center, National Health Commission Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China
| | | | - Yang Li
- Stemirna Therapeutics, Shanghai, China
| | - Xi-Lin Guo
- Jiangsu Provincial Medical Innovation Center, National Health Commission Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China
| | | | - Bo Yu
- Stemirna Therapeutics, Shanghai, China
| | | | - Bin Luo
- Stemirna Therapeutics, Shanghai, China
| | | | | | | | | | | | - Rong Yan
- Stemirna Therapeutics, Shanghai, China
| | - Yu-Zhou Gui
- Shanghai Xuhui Central Hospital/Xuhui Hospital, Fudan University, Shanghai, China
- Shanghai Engineering Research Center of Phase I Clinical Research & Quality Consistency Evaluation for Drugs, Shanghai, China
| | | | - Jie Wang
- Stemirna Therapeutics, Shanghai, China
| | | | | | | | - Mayfong Mayxay
- University of Health Sciences, Ministry of Health, Vientiane, Laos
| |
Collapse
|
5
|
Wan J, Yang J, Wang Z, Shen R, Zhang C, Wu Y, Zhou M, Chen H, Fu ZF, Sun H, Yi Y, Shen H, Li H, Zhao L. A single immunization with core-shell structured lipopolyplex mRNA vaccine against rabies induces potent humoral immunity in mice and dogs. Emerg Microbes Infect 2023; 12:2270081. [PMID: 37819147 PMCID: PMC10768744 DOI: 10.1080/22221751.2023.2270081] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2023] [Accepted: 10/05/2023] [Indexed: 10/13/2023]
Abstract
The persistence and clinical consequences of rabies virus (RABV) infection have prompted global efforts to develop a safe and effective vaccines against rabies. mRNA vaccines represent a promising option against emerging and re-emerging infectious diseases, gaining particular interest since the outbreak of COVID-19. Herein, we report the development of a highly efficacious rabies mRNA vaccine composed of sequence-modified mRNA encoding RABV glycoprotein (RABV-G) packaged in core-shell structured lipopolyplex (LPP) nanoparticles, named LPP-mRNA-G. The bilayer structure of LPP improves protection and delivery of RABV-G mRNA and allows gradual release of mRNA molecules as the polymer degrades. The unique core-shell structured nanoparticle of LPP-mRNA-G facilitates vaccine uptake and demonstrates a desirable biodistribution pattern with low liver targeting upon intramuscular immunization. Single administration of low-dose LPP-mRNA-G in mice elicited potent humoral immune response and provided complete protection against intracerebral challenge with lethal RABV. Similarly, single immunization of low-dose LPP-mRNA-G induced high levels of virus-neutralizing antibody titers in dogs. Collectively, our data demonstrate the potential of LPP-mRNA-G as a promising next-generation rabies vaccine used in human and companion animals.
Collapse
Affiliation(s)
- Jiawu Wan
- State Key Laboratory of Agricultural Microbiology, Huazhong Agricultural University, Wuhan, People’s Republic of China
- Key Laboratory of Preventive Veterinary Medicine of Hubei Province, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, People’s Republic of China
- Hubei Hongshan Laboratory, Wuhan, People’s Republic of China
- Frontiers Science Center for Animal Breeding and Sustainable Production, Wuhan, People’s Republic of China
| | - Jianmei Yang
- Stemirna Therapeutics, Shanghai, People’s Republic of China
| | - Zongmei Wang
- State Key Laboratory of Agricultural Microbiology, Huazhong Agricultural University, Wuhan, People’s Republic of China
- Key Laboratory of Preventive Veterinary Medicine of Hubei Province, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, People’s Republic of China
- Hubei Hongshan Laboratory, Wuhan, People’s Republic of China
- Frontiers Science Center for Animal Breeding and Sustainable Production, Wuhan, People’s Republic of China
| | - Ruizhong Shen
- Stemirna Therapeutics, Shanghai, People’s Republic of China
| | - Chengguang Zhang
- State Key Laboratory of Agricultural Microbiology, Huazhong Agricultural University, Wuhan, People’s Republic of China
- Key Laboratory of Preventive Veterinary Medicine of Hubei Province, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, People’s Republic of China
- Hubei Hongshan Laboratory, Wuhan, People’s Republic of China
- Frontiers Science Center for Animal Breeding and Sustainable Production, Wuhan, People’s Republic of China
| | - Yuntao Wu
- Stemirna Therapeutics, Shanghai, People’s Republic of China
| | - Ming Zhou
- State Key Laboratory of Agricultural Microbiology, Huazhong Agricultural University, Wuhan, People’s Republic of China
- Key Laboratory of Preventive Veterinary Medicine of Hubei Province, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, People’s Republic of China
- Hubei Hongshan Laboratory, Wuhan, People’s Republic of China
- Frontiers Science Center for Animal Breeding and Sustainable Production, Wuhan, People’s Republic of China
| | - Huanchun Chen
- State Key Laboratory of Agricultural Microbiology, Huazhong Agricultural University, Wuhan, People’s Republic of China
- Key Laboratory of Preventive Veterinary Medicine of Hubei Province, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, People’s Republic of China
- Hubei Hongshan Laboratory, Wuhan, People’s Republic of China
- Frontiers Science Center for Animal Breeding and Sustainable Production, Wuhan, People’s Republic of China
| | - Zhen F. Fu
- State Key Laboratory of Agricultural Microbiology, Huazhong Agricultural University, Wuhan, People’s Republic of China
- Key Laboratory of Preventive Veterinary Medicine of Hubei Province, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, People’s Republic of China
- Hubei Hongshan Laboratory, Wuhan, People’s Republic of China
- Frontiers Science Center for Animal Breeding and Sustainable Production, Wuhan, People’s Republic of China
| | - Haiwei Sun
- Stemirna Therapeutics, Shanghai, People’s Republic of China
| | - Yinglei Yi
- Stemirna Therapeutics, Shanghai, People’s Republic of China
| | - Haifa Shen
- Stemirna Therapeutics, Shanghai, People’s Republic of China
| | - Hangwen Li
- Stemirna Therapeutics, Shanghai, People’s Republic of China
| | - Ling Zhao
- State Key Laboratory of Agricultural Microbiology, Huazhong Agricultural University, Wuhan, People’s Republic of China
- Key Laboratory of Preventive Veterinary Medicine of Hubei Province, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, People’s Republic of China
- Hubei Hongshan Laboratory, Wuhan, People’s Republic of China
- Frontiers Science Center for Animal Breeding and Sustainable Production, Wuhan, People’s Republic of China
| |
Collapse
|
6
|
Zhang G, Shen H, Long Y, Lin Y, Chen RC, Gao H. A New Treatment Planning Method for Efficient Proton ARC Therapy with Direct Minimization of Number of Energy Jumps. Int J Radiat Oncol Biol Phys 2023; 117:e716. [PMID: 37786092 DOI: 10.1016/j.ijrobp.2023.06.2220] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) The optimization of energy layer distributions is crucial for efficient proton ARC therapy: on one hand, a sufficient number of energy layers is needed to ensure the plan quality; on the other hand, an excess number of energy jumps can substantially slow down the treatment delivery. This work will develop a new treatment plan optimization method with direct minimization of number of energy jumps (NEJ), which will be shown to outperform state-of-the-art methods in both plan quality and delivery efficiency. MATERIALS/METHODS The proposed method jointly optimizes the plan quality and minimizes the NEJ. To minimize NEJ, (1) the proton spots x is summed per energy layer to form the energy vector y; (2) y is binarized via sigmoid transform into y1; (3) y1 is multiplied with a predefined energy order vector via dot product into y2; (4) y2 is filtered through the finite-differencing kernel into y3 in order to identify NEJ; (5) only the NEJ of y3 is penalized, while x is optimized for plan quality. The solution algorithm to this new method is based on iterative convex relaxation. RESULTS The new method is validated in comparison with state-of-the-art methods called energy sequencing (ES) method and energy matrix (EM) method. In terms of delivery efficiency, the new method had fewer NEJ, less energy switching time, and generally less total delivery time. In terms of plan quality, the new method had smaller optimization objective values, lower normal tissue dose, and generally better target coverage. A head-and-neck case is provided in the table with the following dosimetric parameters: planning objective value F; conformity index CI; homogeneity index HI; mean dose of larynx DOAR; mean body dose Dbody; the unit of dose is Gy. CONCLUSION We have developed a new treatment plan optimization method with direct minimization of NEJ, and demonstrated that this new method outperformed state-of-the-art methods (ES and EM) in both plan quality and delivery efficiency.
Collapse
Affiliation(s)
- G Zhang
- University of Michigan-Shanghai Jiao Tong University Joint Institute, Shanghai Jiao Tong University, Shanghai, China
| | - H Shen
- University of Michigan-Shanghai Jiao Tong University Joint Institute, Shanghai Jiao Tong University, Shanghai, China; Department of Radiation Oncology, University of Kansas Medical Center, Kansas City, KS
| | - Y Long
- University of Michigan-Shanghai Jiao Tong University Joint Institute, Shanghai Jiao Tong University, Shanghai, China
| | - Y Lin
- Department of Radiation Oncology, University of Kansas Medical Center, Kansas City, KS
| | - R C Chen
- Department of Radiation Oncology, University of Kansas Medical Center, Kansas City, KS
| | - H Gao
- Department of Radiation Oncology, University of Kansas Medical Center, Kansas City, KS
| |
Collapse
|
7
|
Zhou M, Zhao J, Tian M, Song S, Zhang R, Gupta S, Tan D, Shen H, Ferrari M, Li C. Retraction: Radio-photothermal therapy mediated by a single compartment nanoplatform depletes tumor initiating cells and reduces lung metastasis in the orthotopic 4T1 breast tumor model. Nanoscale 2023; 15:14268. [PMID: 37592914 PMCID: PMC10528023 DOI: 10.1039/d3nr90158k] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 08/19/2023]
Abstract
Retraction of 'Radio-photothermal therapy mediated by a single compartment nanoplatform depletes tumor initiating cells and reduces lung metastasis in the orthotopic 4T1 breast tumor model' by Min Zhou et al., Nanoscale, 2015, 7, 19438-19447, https://doi.org/10.1039/C5NR04587H.
Collapse
Affiliation(s)
- Min Zhou
- Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
- The Second Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China
| | - Jun Zhao
- Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
| | - Mei Tian
- The Second Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China
| | - Shaoli Song
- Department of Nuclear Medicine, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200127, China
| | - Rui Zhang
- Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
| | - Sanjay Gupta
- Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
| | - Dongfeng Tan
- Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
| | - Haifa Shen
- Department of Nanomedicine, The Methodist Hospital System Research Institute, Houston, TX 77030, USA
| | - Mauro Ferrari
- Department of Nanomedicine, The Methodist Hospital System Research Institute, Houston, TX 77030, USA
| | - Chun Li
- Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
| |
Collapse
|
8
|
Zhang H, Zhang L, Lin A, Xu C, Li Z, Liu K, Liu B, Ma X, Zhao F, Jiang H, Chen C, Shen H, Li H, Mathews DH, Zhang Y, Huang L. Algorithm for optimized mRNA design improves stability and immunogenicity. Nature 2023; 621:396-403. [PMID: 37130545 PMCID: PMC10499610 DOI: 10.1038/s41586-023-06127-z] [Citation(s) in RCA: 39] [Impact Index Per Article: 39.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2022] [Accepted: 04/25/2023] [Indexed: 05/04/2023]
Abstract
Messenger RNA (mRNA) vaccines are being used to combat the spread of COVID-19 (refs. 1-3), but they still exhibit critical limitations caused by mRNA instability and degradation, which are major obstacles for the storage, distribution and efficacy of the vaccine products4. Increasing secondary structure lengthens mRNA half-life, which, together with optimal codons, improves protein expression5. Therefore, a principled mRNA design algorithm must optimize both structural stability and codon usage. However, owing to synonymous codons, the mRNA design space is prohibitively large-for example, there are around 2.4 × 10632 candidate mRNA sequences for the SARS-CoV-2 spike protein. This poses insurmountable computational challenges. Here we provide a simple and unexpected solution using the classical concept of lattice parsing in computational linguistics, where finding the optimal mRNA sequence is analogous to identifying the most likely sentence among similar-sounding alternatives6. Our algorithm LinearDesign finds an optimal mRNA design for the spike protein in just 11 minutes, and can concurrently optimize stability and codon usage. LinearDesign substantially improves mRNA half-life and protein expression, and profoundly increases antibody titre by up to 128 times in mice compared to the codon-optimization benchmark on mRNA vaccines for COVID-19 and varicella-zoster virus. This result reveals the great potential of principled mRNA design and enables the exploration of previously unreachable but highly stable and efficient designs. Our work is a timely tool for vaccines and other mRNA-based medicines encoding therapeutic proteins such as monoclonal antibodies and anti-cancer drugs7,8.
Collapse
Affiliation(s)
- He Zhang
- Baidu Research USA, Sunnyvale, CA, USA
- School of EECS, Oregon State University, Corvallis, OR, USA
| | - Liang Zhang
- Baidu Research USA, Sunnyvale, CA, USA
- School of EECS, Oregon State University, Corvallis, OR, USA
- Vaccine Center, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China
| | - Ang Lin
- StemiRNA Therapeutics, Shanghai, China
- Vaccine Center, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China
| | | | - Ziyu Li
- Baidu Research USA, Sunnyvale, CA, USA
| | - Kaibo Liu
- Baidu Research USA, Sunnyvale, CA, USA
- School of EECS, Oregon State University, Corvallis, OR, USA
| | - Boxiang Liu
- Baidu Research USA, Sunnyvale, CA, USA
- Department of Pharmacy, National University of Singapore, Singapore, Singapore
| | | | | | | | | | | | | | - David H Mathews
- Department of Biochemistry and Biophysics, University of Rochester Medical Center, Rochester, NY, USA.
- Center for RNA Biology, University of Rochester Medical Center, Rochester, NY, USA.
- Department of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, NY, USA.
- Coderna.ai, Inc., Sunnyvale, CA, USA.
| | - Yujian Zhang
- StemiRNA Therapeutics, Shanghai, China.
- , Gaithersburg, MD, USA.
| | - Liang Huang
- Baidu Research USA, Sunnyvale, CA, USA.
- School of EECS, Oregon State University, Corvallis, OR, USA.
- Coderna.ai, Inc., Sunnyvale, CA, USA.
| |
Collapse
|
9
|
Liang JY, Jing Y, Shen H, Chen XJ, Luo WJ, Song Y, Wang Y, Hu JB, Yang SM, Wu FF, Li QF. [Distribution characteristics of plasma renin concentration in patients with aldosterone-producing adenoma]. Zhonghua Nei Ke Za Zhi 2023; 62:972-978. [PMID: 37528035 DOI: 10.3760/cma.j.cn112138-20230105-00007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Subscribe] [Scholar Register] [Indexed: 08/03/2023]
Abstract
Objective: To analyze the distribution characteristics of plasma renin concentration (PRC) in patients with aldosterone-producing adenoma (APA) and its impact on diagnosis. Methods: In this retrospective case series, clinical data from 200 patients with APA (80 men and 120 women; mean age 45.6 years) in the First Affiliated Hospital of Chongqing Medical University from November 2013 to January 2022 were evaluated. PRC was determined by automated chemiluminescence immunoassay. The distribution characteristics of PRC were analyzed, and 8.2 mU/L was used as the low renin cutoff to evaluate whether renin was suppressed. Results: The median PRC was 1.6 mU/L (range, 0.4-41.5 mU/L). There were 116 patients with APA with PRC of ≤2 mU/L, 41 patients with 2<PRC≤4 mU/L. PRC was not suppressed (PRC>8.2 mU/L) in 8.0% (16/200) of the patients with APA. And PRC was not suppressed in 2.5% (5/200) of the patients with APA, resulting in a primary aldosteronism negative screening outcome. Conclusions: Although most patients with APA have low PRC, there are a small number (8%) of patients whose PRC has not been fully suppressed, which can lead to missed diagnoses during primary aldosteronism screening. While primary aldosteronism is highly suspected, further investigations are required to determine the diagnosis, even if PRC is not fully suppressed at screening.
Collapse
Affiliation(s)
- J Y Liang
- Department of Endocrinology, the First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
| | - Y Jing
- Department of Endocrinology, the First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
| | - H Shen
- Department of Endocrinology, the First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
| | - X J Chen
- Department of Endocrinology, the First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
| | - W J Luo
- Department of Endocrinology, the First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
| | - Y Song
- Department of Endocrinology, the First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
| | - Y Wang
- Department of Endocrinology, the First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
| | - J B Hu
- Department of Endocrinology, the First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
| | - S M Yang
- Department of Endocrinology, the First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
| | - F F Wu
- Department of Endocrinology, Heping Hospital Affiliated to Changzhi Medical College, Changzhi 046099, China
| | - Q F Li
- Department of Endocrinology, the First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
| |
Collapse
|
10
|
Fei J, Shen H, Yang SM, Du ZP, Hu JB, Wang HB, Qin GJ, Ji HF, Li QF, Song Y. [Establishment and validation of a nomogram-based predictive model for idiopathic aldosteronism]. Zhonghua Nei Ke Za Zhi 2023; 62:693-699. [PMID: 37263953 DOI: 10.3760/cma.j.cn112138-20221108-00836] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
Objective: To establish and validate a nomogram-based predictive model for idiopathic hyperaldosteronism (IHA). Methods: This cross-sectional study was conducted with the collected clinical and biochemical data of patients with primary aldosteronism (PA) including 249 patients with unilateral primary aldosteronism (UPA) and 107 patients with IHA, who were treated at the Department of Endocrinology of the First Affiliated Hospital of Chongqing Medical University from November 2013 to November 2022. Plasma aldosterone concentration (PAC) and plasma renin concentration (PRC) were measured by chemiluminescence. Stepwise regression analysis was applied to select the key predictors of IHA, and a nomogram-based scoring model was developed. The model was validated in another external independent cohort of patients with PA including 62 patients with UPA and 43 patients with IHA, who were diagnosed at the Department of Endocrinology, First Affiliated Hospital of Zhengzhou University. An independent-sample t test, Mann-Whitney U test, and χ2 test were used for statistical analysis. Results: In the training cohort, in comparison with the UPA group, the IHA group showed a higher serum potassium level [M(Q1, Q3), 3.4 (3.1, 3.8) mmol/L vs. 2.7 (2.1, 3.1) mmol/L] and higher PRC [4.0 (2.1, 8.2) mU/L vs. 1.5 (0.6, 3.4) mU/L] and a lower PAC post-saline infusion test (SIT) [305 (222, 416) pmol/L vs. 720 (443, 1 136) pmol/L] and a lower rate of unilateral adrenal nodules [33.6% (36/107) vs. 81.1% (202/249)]; the intergroup differences in these measurements were statistically significant (all P<0.001). Serum potassium level, PRC, PAC post-SIT, and the rate of unilateral adrenal nodules showed similar performance in the IHA group in the validation cohort. After stepwise regression analysis for all significant variables in the training cohort, a scoring model based on a nomogram was constructed, and the predictive parameters included the rate of unilateral adrenal nodules, serum potassium concentration, PAC post-SIT, and PRC in the standing position. When the total score was ≥14, the model showed a sensitivity of 0.65 and specificity of 0.90 in the training cohort and a sensitivity of 0.56 and specificity of 1.00 in the validation cohort. Conclusion: The nomogram was used to successfully develop a model for prediction of IHA that could facilitate selection of patients with IHA who required medication directly.
Collapse
Affiliation(s)
- J Fei
- Department of Endocrinology, the First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
| | - H Shen
- Department of Endocrinology, the First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
| | - S M Yang
- Department of Endocrinology, the First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
| | - Z P Du
- Department of Endocrinology, the First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
| | - J B Hu
- Department of Endocrinology, the First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
| | - H B Wang
- Department of Endocrinology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
| | - G J Qin
- Department of Endocrinology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
| | - H F Ji
- Department of Endocrinology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
| | - Q F Li
- Department of Endocrinology, the First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
| | - Y Song
- Department of Endocrinology, the First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
| |
Collapse
|
11
|
Ko CC, Merodio MM, Spronk E, Lehman JR, Shen H, Li G, Derscheid RJ, Piñeyro PE. Diagnostic investigation of Mycoplasma hyorhinis as a potential pathogen associated with neurological clinical signs and central nervous system lesions in pigs. Microb Pathog 2023; 180:106172. [PMID: 37230257 DOI: 10.1016/j.micpath.2023.106172] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2023] [Revised: 05/23/2023] [Accepted: 05/23/2023] [Indexed: 05/27/2023]
Abstract
Mycoplasma hyorhinis (M. hyorhinis) is a commensal of the upper respiratory tract in swine with the typical clinical presentations of arthritis and polyserositis in postweaning pigs. However, it has also been associated with conjunctivitis and otitis media, and recently has been isolated from meningeal swabs and/or cerebrospinal fluid of piglets with neurological signs. The objective of this study is to evaluate the role of M. hyorhinis as a potential pathogen associated with neurological clinical signs and central nervous system lesions in pigs. The presence of M. hyorhinis was evaluated in a clinical outbreak and a six-year retrospective study by qPCR detection, bacteriological culture, in situ hybridization (RNAscope®), and phylogenetic analysis and with immunohistochemistry characterization of the inflammatory response associated with its infection. M. hyorhinis was confirmed by bacteriological culture and within central nervous system lesions by in situ hybridization on animals with neurological signs during the clinical outbreak. The isolates from the brain had close genetic similarities from those previously reported and isolated from eye, lung, or fibrin. Nevertheless, the retrospective study confirmed by qPCR the presence of M. hyorhinis in 9.9% of cases reported with neurological clinical signs and histological lesions of encephalitis or meningoencephalitis of unknown etiology. M. hyorhinis mRNA was confirmed within cerebrum, cerebellum, and choroid plexus lesions by in situ hybridization (RNAscope®) with a positive rate of 72.7%. Here we present strong evidence that M. hyorhinis should be included as a differential etiology in pigs with neurological signs and central nervous system inflammatory lesions.
Collapse
Affiliation(s)
- Calvin C Ko
- Department of Veterinary Diagnostic and Production Animal Medicine, College of Veterinary Medicine, Iowa State University, Ames, IA, USA
| | - Maria M Merodio
- Department of Biomedical Sciences, College of Veterinary Medicine, Iowa State University, Ames, IA, USA
| | - E Spronk
- Swine Vet Center P.A., 1608 South Minnesota Avenue, St. Peter, Minnesota, USA
| | - J R Lehman
- Swine Technical Services, Merck Animal Health, Lenexa, KS, USA
| | - H Shen
- Department of Veterinary Diagnostic and Production Animal Medicine, College of Veterinary Medicine, Iowa State University, Ames, IA, USA
| | - G Li
- Department of Veterinary Diagnostic and Production Animal Medicine, College of Veterinary Medicine, Iowa State University, Ames, IA, USA
| | - Rachel J Derscheid
- Department of Veterinary Diagnostic and Production Animal Medicine, College of Veterinary Medicine, Iowa State University, Ames, IA, USA
| | - Pablo E Piñeyro
- Department of Veterinary Diagnostic and Production Animal Medicine, College of Veterinary Medicine, Iowa State University, Ames, IA, USA.
| |
Collapse
|
12
|
Zhang C, Huang L, Tang Y, Wang P, Chen Y, Zhang L, Shen H, Yu Y, Tian X, Wang Y. [Identification and verification of α-11 giardin-interacting protein]. Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi 2023; 35:155-162. [PMID: 37253564 DOI: 10.16250/j.32.1374.2022288] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
OBJECTIVE To identify and verify the interacting protein of α-11 giardin, so as provide the experimental evidence for studies on the α-11 giardin function. METHODS The yeast two-hybrid cDNA library of the Giardia lambia C2 strain and the bait plasmid of α-11 giardin were constructed. All proteins interacting with α-11 giardin were screened using the yeast two-hybrid system. α-11 giardin and all screened potential interacting protein genes were constructed into pBiFc-Vc-155 and pBiFc-Vn-173 plasmids, and co-transfected into the breast cancer cell line MDA-MB-231. The interactions between α-11 giardin and interacting proteins were verified using bimolecular fluorescence complementation (BiFC). RESULTS The yeast two-hybrid G. lambia cDNA library which was quantified at 2.715 × 107 colony-forming units (CFU) and the bait plasmid containing α-11 giardin gene without an autoactivation activity were constructed. Following two-round positive screening with the yeast two-hybrid system, two potential proteins interacting with α-11 giardin were screened, including eukaryotic translation initiation factor 5A (EIF5A), calmodulin-dependent protein kinase (CAMKL) and nicotinamide adenine dinucleotide phosphate-specific glutamate dehydrogenase (NADP-GDH), hypothetical protein 1 (GL50803_95880), hypothetical protein 2 (GL50803_87261) and a protein from Giardia canis virus. The α-11 giardin and EIF5A genes were transfected into the pBiFc-Vc-155 and pBiFc-Vn-173 plasmids using BiFC, and the recombinant plasmids pBiFc-Vc-155-α-11 and pBiFc-Vn-173-EIF5A were co-tranfected into MDA-MB-231 cells, which displayed green fluorescence under a microscope, indicating the interaction between α-11 giardin and EIF5A protein in cells. CONCLUSIONS The yeast two-hybrid cDNA library of the G. lambia C2 strain has been successfully constructed, and six potential protein interacting with α-11 giardin have been identified, including EIF5A that interacts with α-11 giardin in cells.
Collapse
Affiliation(s)
- C Zhang
- College of Life Sciences, North China University of Technology, Tangshan, Hebei 063000, China
| | - L Huang
- Hongci Hospital of Tangshan City, Hebei Province, China
| | - Y Tang
- College of Life Sciences, North China University of Technology, Tangshan, Hebei 063000, China
| | - P Wang
- College of Life Sciences, North China University of Technology, Tangshan, Hebei 063000, China
| | - Y Chen
- College of Life Sciences, North China University of Technology, Tangshan, Hebei 063000, China
| | - L Zhang
- College of Life Sciences, North China University of Technology, Tangshan, Hebei 063000, China
| | - H Shen
- College of Life Sciences, North China University of Technology, Tangshan, Hebei 063000, China
| | - Y Yu
- College of Life Sciences, North China University of Technology, Tangshan, Hebei 063000, China
| | - X Tian
- College of Life Sciences, North China University of Technology, Tangshan, Hebei 063000, China
| | - Y Wang
- College of Life Sciences, North China University of Technology, Tangshan, Hebei 063000, China
| |
Collapse
|
13
|
Gui YZ, Li XN, Li JX, Shen MY, Zhang MW, Cao Y, Xu HR, Li H, Cheng J, Pan L, Yi YL, Liang LY, Yu CY, Liu GY, Yu C, Hu BJ, Zhu FC, Liang F, Shen H, Jia JY, Li HW, Zhou J, Fan J. Safety and immunogenicity of a modified COVID-19 mRNA vaccine, SW-BIC-213, as a heterologous booster in healthy adults: an open-labeled, two-centered and multi-arm randomised, phase 1 trial. EBioMedicine 2023; 91:104586. [PMID: 37099843 PMCID: PMC10124970 DOI: 10.1016/j.ebiom.2023.104586] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2022] [Revised: 04/10/2023] [Accepted: 04/10/2023] [Indexed: 04/28/2023] Open
Abstract
BACKGROUND We assessed the safety and immunogenicity of a core-shell structured lipopolyplex (LPP) based COVID-19 mRNA vaccine, SW-BIC-213, as a heterologous booster in healthy adults. METHODS We conducted an open-labeled, two-centered, and three-arm randomised phase 1 trial. Healthy adults, who had completed a two-dose of inactivated COVID-19 vaccine for more than six months, were enrolled and randomized to receive a booster dose of COVILO (inactivated vaccine) (n = 20) or SW-BIC-213-25μg (n = 20), or SW-BIC-213-45μg (n = 20). The primary study endpoint was adverse events within 30 days post-boosting. The secondary endpoint was the titers of binding antibodies and neutralizing antibodies against the wild-type (WT) of SARS-CoV-2 as well as variants of concern in serum. The exploratory endpoint was the cellular immune responses. This trial was registered with http://www.chictr.org.cn (ChiCTR2200060355). FINDINGS Between Jun 6 and Jun 22, 2022, 60 participants were enrolled and randomized to receive a booster dose of SW-BIC-213 (25 μg, n = 20, or 45 μg, n = 20) or COVILO (n = 20). The baseline demographic characteristics of the participants at enrollment were similar among the treatment groups. For the primary outcome, injection site pain and fever were more common in the SW-BIC-213 groups (25 μg and 45 μg). Grade 3 fever was reported in 25% (5/20) of participants in the SW-BIC-213-45μg group but was resolved within 48 h after onset. No fatal events or adverse events leading to study discontinuation were observed. For secondary and exploratory outcomes, SW-BIC-213 elicited higher and longer humoral and cellular immune responses than that in the COVILO group. INTERPRETATION SW-BIC-213, a core-shell structured lipopolyplex (LPP) based mRNA vaccine, was safe, tolerable, and immunogenic as a heterologous booster in healthy Chinese adults. FUNDING Shanghai Municipal Government, the Science and Technology and Economic Commission of Shanghai Pudong New Area, and mRNA Innovation and Translation Center of Shanghai.
Collapse
Affiliation(s)
- Yu-Zhou Gui
- Shanghai Xuhui Central Hospital/Xuhui Hospital, Fudan University, Shanghai, China; Shanghai Engineering Research Center of Phase I Clinical Research & Quality Consistency Evaluation for Drugs, Shanghai, China
| | - Xue-Ning Li
- Zhongshan Hospital, Fudan University, Shanghai, China
| | - Jing-Xin Li
- Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China
| | | | - Mei-Wei Zhang
- Shanghai Xuhui Central Hospital/Xuhui Hospital, Fudan University, Shanghai, China; Shanghai Engineering Research Center of Phase I Clinical Research & Quality Consistency Evaluation for Drugs, Shanghai, China
| | - Ye Cao
- Shanghai Xuhui Central Hospital/Xuhui Hospital, Fudan University, Shanghai, China; Shanghai Engineering Research Center of Phase I Clinical Research & Quality Consistency Evaluation for Drugs, Shanghai, China
| | - Hong-Rong Xu
- Zhongshan Hospital, Fudan University, Shanghai, China
| | - Hui Li
- Zhongshan Hospital, Fudan University, Shanghai, China
| | - Jie Cheng
- Zhongshan Hospital, Fudan University, Shanghai, China
| | - Liang Pan
- Shanghai Xuhui Central Hospital/Xuhui Hospital, Fudan University, Shanghai, China; Shanghai Engineering Research Center of Phase I Clinical Research & Quality Consistency Evaluation for Drugs, Shanghai, China
| | - Ying-Lei Yi
- StemiRNA Therapeutics Co., Ltd., Shanghai, China
| | - Li-Yu Liang
- Shanghai Xuhui Central Hospital/Xuhui Hospital, Fudan University, Shanghai, China; Shanghai Engineering Research Center of Phase I Clinical Research & Quality Consistency Evaluation for Drugs, Shanghai, China
| | - Cheng-Yin Yu
- Shanghai Xuhui Central Hospital/Xuhui Hospital, Fudan University, Shanghai, China; Shanghai Engineering Research Center of Phase I Clinical Research & Quality Consistency Evaluation for Drugs, Shanghai, China
| | - Gang-Yi Liu
- Shanghai Xuhui Central Hospital/Xuhui Hospital, Fudan University, Shanghai, China; Shanghai Engineering Research Center of Phase I Clinical Research & Quality Consistency Evaluation for Drugs, Shanghai, China
| | - Chen Yu
- Shanghai Xuhui Central Hospital/Xuhui Hospital, Fudan University, Shanghai, China; Shanghai Engineering Research Center of Phase I Clinical Research & Quality Consistency Evaluation for Drugs, Shanghai, China
| | - Bi-Jie Hu
- Zhongshan Hospital, Fudan University, Shanghai, China
| | - Feng-Cai Zhu
- Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China
| | - Fei Liang
- Zhongshan Hospital, Fudan University, Shanghai, China
| | - Haifa Shen
- StemiRNA Therapeutics Co., Ltd., Shanghai, China
| | - Jing-Ying Jia
- Shanghai Xuhui Central Hospital/Xuhui Hospital, Fudan University, Shanghai, China; Shanghai Engineering Research Center of Phase I Clinical Research & Quality Consistency Evaluation for Drugs, Shanghai, China
| | - Hang-Wen Li
- StemiRNA Therapeutics Co., Ltd., Shanghai, China
| | - Jian Zhou
- Zhongshan Hospital, Fudan University, Shanghai, China
| | - Jia Fan
- Zhongshan Hospital, Fudan University, Shanghai, China.
| |
Collapse
|
14
|
Liu Y, Yu D, Mai J, Pan PY, Chen SH, Shen H. Abstract 2006: A novel macromolecular platinum drug with potent efficacy to overcome cross-resistance in cancer therapy. Cancer Res 2023. [DOI: 10.1158/1538-7445.am2023-2006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/07/2023]
Abstract
Abstract
Background: Small molecular platinum (Pt)-based drugs such as cisplatin, carboplatin, and oxaliplatin have achieved great success in clinic over 40 years in cancer therapy. However, lack of tumor specificity leads to severe side effects. In addition, cancer cells frequently develop resistance to treatment through overexpressing cell surface multi-drug resistant proteins (MDRs). Therefore, it is desirable to develop novel Pt-based drugs with excellent anti-cancer efficacy and a minimal toxicity profile, as well as the capability to overcome drug resistance. We have previously demonstrated that poly(amino acid)-conjugated drugs can reduce toxicity and improve pharmacokinetics of chemotherapeutics and also overcome drug resistance by bypassing MDRs. Here we would like to apply this strategy on Pt drug development.
Method: To address this question, we synthesized a L-aspartic acid-chelated Pt moieties (Asp-Pt), and then conjugated it to poly(L-glutamic acid/L-aspartic acid) to generate a polymeric-Pt macromolecule, namely carrier-platin. We next applied this drug on cancer cell lines including the therapeutic-resistant cancer cells in vitro, and tumor bearing murine models in vivo to evaluate its efficacy and toxicity.
Result: We first tested the cytotoxicity of carrier-platin and compared with a current first-line chemotherapeutic oxaliplatin on colorectal cancer cell CT26 in vitro. Surprisingly, we found that carrier-platin effectively killed the CT26 cancer cells with hours while oxaliplatin slowly induced cell death after days. Importantly, carrier-platin was well-tolerated by non-cancerous cells. Furthermore, carrier-platin killed cancer cells that resistant to current chemotherapeutics in clinic, including cisplatin, oxaliplatin, doxorubicin and docetaxel, as effective as their parental cells. Next, we found that carrier-platin showed prolonged circulation time and high tumor accumulation compared with Pt-equivalent dosage of oxaliplatin. Treatment with 8 mg Pt/kg oxaliplatin caused severe body weight loss and intolerable hematotoxicity in mice, but even higher dose of carrier-platin (12 mg Pt/kg) can be tolerated by mice with stable body weight and did not induce any clinical symptoms. Finally, we revealed that carrier-platin potently inhibited mouse colorectal (CT26) and human ovarian (A2780) tumor growth over Pt-equivalent dosage of oxaliplatin. More importantly, carrier-platin was almost as effective on the cisplatin-resistant A2780 tumors (A2780-Cis) as on the parental A2780 tumors in vivo.
Conclusion: We developed a novel macromolecular drug carrier-platin that overcome shortages of current small molecular Pt drugs. It displayed a satisfactory toxicity profile accompanied with excellent anti-tumor efficacy in vivo. Moreover, carrier-platin overcomes the cross-resistance problem of cancer cells to current chemotherapeutic drugs.
Citation Format: Yongbin Liu, Dongfang Yu, Junhua Mai, Ping-Ying Pan, Shu-Hsia Chen, Haifa Shen. A novel macromolecular platinum drug with potent efficacy to overcome cross-resistance in cancer therapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 2006.
Collapse
Affiliation(s)
- Yongbin Liu
- 1Houston Methodist Research Institute, Houston, TX
| | - Dongfang Yu
- 1Houston Methodist Research Institute, Houston, TX
| | - Junhua Mai
- 1Houston Methodist Research Institute, Houston, TX
| | | | | | - Haifa Shen
- 1Houston Methodist Research Institute, Houston, TX
| |
Collapse
|
15
|
Mai J, Liu Y, Yu D, Shen H. Abstract 6799: A porous silicon particle based particulate anti-cancer vaccine for immunotherapy. Cancer Res 2023. [DOI: 10.1158/1538-7445.am2023-6799] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/07/2023]
Abstract
Abstract
Background: Anti-cancer vaccine is a widely-studied strategy that activates innate and adaptive host immunity via its adjuvant components and tumor antigens against cancer. Unfortunately, its response rate in clinical trials was not promising. On the vaccine part, sufficient stimulation of strong and long-lasting local and systemic immunity and efficient promotion of intratumoral infiltration of cytotoxic T lymphocytes are among the critical issues determining the therapeutic efficacy of cancer vaccines in addition to the innate features of tumor. Our project aims to develop a porous silicon particle based particulate vaccine against cancer, and investigate the therapeutic mechanism and combinational effects with current first-line strategies.
Method: We first screened the combinations of ligands of Toll-like receptors (TLRs) expressing on antigen presenting cells (APCs) and selected the most powerful combo for immune stimulation. We then loaded the identified adjuvants in addition to antigen peptides to produce vaccine particles. Stimulation and licensing of APCs were tested in vitro, and its therapeutic efficacies were evaluated on multiple orthotopic and systemic metastasis cancer murine models of breast and colon cancers. Furthermore, we investigated the vaccine’s synergistic effects and impacts on tumor microenviroment (TME) with an immunogenic chemotherapeutic oxaliplatin on a CT26 colon cancer model.
Result: According to the adjuvant screening assays, we identified a capable combination of CpG1826 (CpG) and 2’3’-cGAMP (cGAMP), which extensively stimulated the activation, maturation and type-I interferon secretion of APCs. A µGCVax formulation composed by these two adjuvants and antigen peptides was then applied on primary and metastatic HER2+ breast cancer TUBO bearing mice. µGCVax potently promoted the activation and lymph node migration of CD8+ and CD103+ dendritic cells in vivo. Distal metastatic tumor nodules in all different tissues vanished after two vaccinations. Functional cure of cancer and extension of animal survival were achieved. Moreover, oxaliplatin treatment on colon cancer caused immunogenic cell death and generated an immune favorable TME in a subcutaneous CT26 colon cancer model. The combination of µGCVax with the oxaliplatin effectively blocked the progression of large tumor mass. We finally revealed that the reprogramming of TME and the promotion of efficacy were mostly achieved from diminishing myeloid-derived suppressor cells (MDSCs) in tumor.
Conclusion: µGCVax is an effective and board-spectrum formulation for cancer immunotherapy. It effectively induces APC activation and licensing, and stimulates the innate and adaptive immunity against multiple cancers. The combination with oxaliplatin further promotes the therapeutic efficacy of µGCVax by decreasing tumor MDSCs.
Citation Format: Junhua Mai, Yongbin Liu, Dongfang Yu, Haifa Shen. A porous silicon particle based particulate anti-cancer vaccine for immunotherapy. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 6799.
Collapse
Affiliation(s)
- Junhua Mai
- 1Houston Methodist Research Institute, Houston, TX
| | - Yongbin Liu
- 1Houston Methodist Research Institute, Houston, TX
| | - Dongfang Yu
- 1Houston Methodist Research Institute, Houston, TX
| | - Haifa Shen
- 1Houston Methodist Research Institute, Houston, TX
| |
Collapse
|
16
|
Hu J, Tang X, Guo R, Wang Y, Shen H, Wang H, Yao Y, Cai X, Yu Z, Dong G, Liang F, Cao J, Zeng L, Su M, Kong W, Liu L, Huang W, Cai C, Xie Y, Mao W. 37P Pralsetinib in acquired RET fusion-positive advanced non-small cell lung cancer patients after resistance to EGFR/ALK-TKI: A China multi-center, real-world data (RWD) analysis. J Thorac Oncol 2023. [DOI: 10.1016/s1556-0864(23)00291-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/03/2023]
|
17
|
Chen X, He J, Shen H, Xi Y, Chen B, He X, Gao J, Yu H, Shen W. 97P Aumolertinib as adjuvant therapy in postoperative EGFR-mutated stage I–III non-small cell lung cancer with high-risk pathological factors. J Thorac Oncol 2023. [DOI: 10.1016/s1556-0864(23)00352-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/04/2023]
|
18
|
Rosentreter R, Cheng E, Shen H, Ma C, Bhayana D, Panaccione R, Raman M, Medellin A, Lu C. A107 VISCERAL ADIPOSE TISSUE VOLUME DIFFERENTIATES BETWEEN FIBROSTENOTIC AND INFLAMMATORY CROHN’S DISEASE. J Can Assoc Gastroenterol 2023. [PMCID: PMC9991293 DOI: 10.1093/jcag/gwac036.107] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 03/09/2023] Open
Abstract
Background Creeping fat, a form of visceral adipose tissue (VAT) that wraps the intestinal wall, influences the formation of Crohn’s disease (CD) strictures. The degree of fat wrapping from intestinal stricture resections is correlated with the extent of chronic inflammation, fibrosis, stricture formation, and response to biologic therapy. VAT and subcutaneous adipose tissue (SAT) ratios from CTE (computed tomography) scans are elevated in CD strictures. However, the definition of strictures in these studies has been poorly defined and not included current well-recognized criteria: 1) bowel wall thickness (BWT), 2) narrowed luminal diameter, and 3) pre-stenotic dilation. (PSD). Purpose The objective of this pilot study was to assess the relationship of 2D and 3D VAT:SAT ratios with CT stricture parameters in patients with terminal ileal (TI) CD strictures. Method 2D VAT:SAT ratios from CT’s of CD patients with TI strictures defined as increased BWT, narrowed luminal diameter (< 50% relative to normal adjacent distended loop), and PSD greater than the stricture diameter were retrospectively obtained from a database and chart review. CT’s from fibrostenotic CD patients were sex and BMI matched to patients with only TI inflammatory behaviour. Patient demographics, medication, smoking, and surgical history were also obtained. Analyses were adjusted for age, sex, and BMI covariates. Unpaired t-tests and multi-variable logistic regression analyses were conducted. Result(s) Twenty-eight patients with stricturing CD had a significantly greater mean VAT:SAT volume ratio than 29 non-stricturing CD (41.5 cm3 vs 34.2 cm3, p=0.03). Thirty-six percent (10/28) of CD stricture patients had prior ileocolic resection with a mean disease duration of 13.5 years (range 0-48). The median ileal BWT (7.0 mm, range 4.0-13.0 mm) for the stricturing group was significantly greater than those with inflammatory behaviour (BWT 2.0 mm, p<0.0001). The median luminal diameter and PSD for the stricture group was 2.0 mm (range 0 - 14.0 mm), and 3.0 cm (range 1.0 - 7.3 cm), respectively. Image ![]()
Conclusion(s) Fibrostenotic TI CD patients have increased VAT:SAT ratios in comparison to those with only inflammatory behaviour. These pilot VAT:SAT results provide an initial foundation for further studies to assess its predictive role in responsiveness of medical or surgical therapies in stricturing CD. Please acknowledge all funding agencies by checking the applicable boxes below None Disclosure of Interest None Declared
Collapse
Affiliation(s)
| | | | - H Shen
- Department of Mathematics and Statistics
| | - C Ma
- Department of Medicine,Department of Community Health Sciences, University of Calgary, Calgary, Canada
| | | | | | - M Raman
- Department of Medicine,Department of Community Health Sciences, University of Calgary, Calgary, Canada
| | | | | |
Collapse
|
19
|
Wang W, Ni B, Shen H, Lu H. Meta-analysis of InterTan, PFNA and PFNA-II internal fixation for the treatment of unstable intertrochanteric fractures in elderly individuals. Acta Orthop Belg 2023; 89:51-58. [PMID: 37294985 DOI: 10.52628/89.1.9923] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
Elderly individuals are often affected by osteoporosis and have poor stability after fracture reduction. Moreover, there is still controversy regarding the clinical effects of the treatment for unstable intertrochanteric fractures in the elderly. The Cochrane, Embase, PubMed, and other databases were searched, and a meta-analysis of the literature on the treatment of unstable intertrochanteric fractures of the elderly with InterTan, PFNA, and PFNA-II was conducted. Seven studies were screened, with a total of 1236 patients. Our meta-analysis results show that InterTan is not significantly different from PFNA in terms of operation and fluoroscopy times, but it takes longer than PFNA-II. In terms of postoperative screw cut, pain, femoral shaft fracture, and secondary operations, InterTan is superior to PFNA and PFNA-II. Conversely, in terms of intraoperative blood loss, hospital stay, and postoperative Harris score, there is no significant difference between InterTan and PFNA and PFNA-II. Compared to PFNA and PFNA-II, InterTan internal fixation has advantages in the treatment of unstable intertrochanteric fractures in elderly individuals in terms of screw cutting, femoral shaft fractures, and secondary operations. However, InterTan operation and fluoroscopy times take longer than PFNA and PFNA-II.
Collapse
|
20
|
Wang B, Deng Y, Xu Q, Gao J, Shen H, He X, Ding Q, Wang F, Guo H. Exploration of 68Ga-labelled prostate-specific membrane antigen-11 PET/CT parameters for identifying PBRM1 status in primary clear cell renal cell carcinoma. Clin Radiol 2023; 78:e417-e424. [PMID: 36805287 DOI: 10.1016/j.crad.2023.01.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2022] [Revised: 12/26/2022] [Accepted: 01/10/2023] [Indexed: 02/04/2023]
Abstract
AIM To investigate the predictive value of 68Ga-labelled prostate-specific membrane antigen-11 (68Ga-PSMA-11) integrated positron-emission tomography (PET)/computed tomography (CT) in PBRM1-deficient clear cell renal cell carcinoma (ccRCC). MATERIALS AND METHODS A total of 41 patients with ccRCC, were enrolled retrospectively and underwent 68Ga-PSMA-11 PET/CT preoperatively. Radiological parameters, including CT attenuation value and maximum standard uptake value (SUVmax), were derived. Immunohistochemical and multiple immunofluorescences staining were performed to evaluate the PBRM1 status and immune response. The predictive value of imaging factors was analysed using a receiver operator characteristic curve analysis. Univariate and multivariate logistic regression analyses were used to investigate the relationship between clinical and radiological variables and PBRM1 status. RESULTS A total of 41 patients were included in this study, with 14 patients having PBRM1-deficient status. The tumour diameter on imaging and SUVmax differed significantly in patients with different PBRM1 expression statuses and no difference in CT attenuation was identified. Univariate and multivariate logistic regression analyses showed SUVmax was an obvious predictor for identification of PBRM1-deficient tumours. In addition, PBRM1-deficient tumours tended to be accompanied by greater cytotoxic T-cell infiltration, although most of them were in an exhausted state. CONCLUSIONS 68Ga-PSMA-11 PET/CT could be used to discriminate invasive PBRM1-deficient ccRCC.
Collapse
Affiliation(s)
- B Wang
- Department of Urology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China
| | - Y Deng
- Department of Urology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China
| | - Q Xu
- Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China
| | - J Gao
- Department of Urology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China
| | - H Shen
- Department of Urology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China
| | - X He
- Department of Urology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
| | - Q Ding
- Department of Urology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Xuzhou Medical University, Nanjing, Jiangsu, China
| | - F Wang
- Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China
| | - H Guo
- Department of Urology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China; Department of Urology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
| |
Collapse
|
21
|
Guan SW, Wen F, Shen H, Zhao EM, Qin Y, Xiao SF. [Comparison between transoral radiofrequency coblation surgery and open partial laryngectomy for the treatment of supraglottic laryngeal carcinoma]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2022; 57:1457-1462. [PMID: 36707950 DOI: 10.3760/cma.j.cn115330-20220321-00123] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Objective: To explore the feasibility and efficacy of radiofrequency coblation assisted transoral surgery for the treatment of supraglottic laryngeal carcinoma by comparing with concurrent patients treated with conventional transcervical approach. To clarify the advantages of different surgical methods and to summarize the experience of supraglottic carcinoma radiofrequency ablation. Methods: Forty-six patients with supraglottic laryngeal carcinoma treated in department of otorhinolaryngology head and neck surgery, Peking University First Hospital from March 2014 to January 2021 were analyzed retrospectively. Among them(43 males, 3 females, aged from 45 to 79 years old), 23 patients were treated with radiofrequency coblation and 23 patients with partial laryngectomy with conventional transcervical approach. The operation time, intra-operative blood loss volume, recovery time, inpatient total medical cost and follow-up information of the two groups were analyzed. SPSS 26.0 software was used for statistical analysis. Results: There were no significant differences in age, gender, TNM staging,tumor staging and postoperative radiotherapy between the two groups (all P>0.05).The operation time, intra-operative blood loss volume, recovery time, inpatient total medical cost of the RFC-TOS group were110.0(60.0,150.0)min,5.0(5.0,30.0)ml,3.0(2.0,5.0)days,6.0(4.0,14.0)days and 26 100.7(16 145.5,47 044.4)yuan. The data of conventional transcervical approach group were 205.0(156.5,272.3)min, 150.0(50,200) ml, 18.0(16.3,22.8)days and 56520.1(440 992.5,67 109.9)yuan, (Z=-4.03, -4.94, -4.97, -4.98 and -4.13;all P<0.001).The 5-year local control rate, disease-specific survival rate and overall survival rate of the two groups were 86.96%,95.65%,91.30% and 86.96%,91.30%,73.90% renspectively, which had no significant difference between the two groups(all P>0.05). Conclusions: Compared with conventional transcervical surgeries, RFC-TOS could be a reliable new surgical option for organ-function preservation strategy in the treatment of supraglottic laryngeal carcinoma.The RFC is a suitable new technique and deserving more multi-center clinical trials for its clinical promotion.
Collapse
Affiliation(s)
- S W Guan
- Department of Otorhinolaryngology Head and Neck Surgery, Peking University First Hospital, Beijing 100034, China
| | - F Wen
- Department of Otorhinolaryngology Head and Neck Surgery, Peking University First Hospital, Beijing 100034, China
| | - H Shen
- Department of Otorhinolaryngology Head and Neck Surgery, Peking University First Hospital, Beijing 100034, China
| | - E M Zhao
- Department of Otorhinolaryngology Head and Neck Surgery, Peking University First Hospital, Beijing 100034, China
| | - Y Qin
- Department of Otorhinolaryngology Head and Neck Surgery, Peking University First Hospital, Beijing 100034, China
| | - S F Xiao
- Department of Otorhinolaryngology Head and Neck Surgery, Peking University First Hospital, Beijing 100034, China
| |
Collapse
|
22
|
Shu Y, Ma P, Shen H, Gao W, Chen X, Sun J, Xu L. 145P Preliminary results of a phase Ⅱ study of fruquintinib combined with sintilimab and chemotherapy as the first-line treatment in advanced naive EGFR- and ALK-negative non-squamous non-small cell lung cancer (nsq-NSCLC). Immuno-Oncology and Technology 2022. [DOI: 10.1016/j.iotech.2022.100257] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
23
|
Gee H, Szymd R, Casolin S, French L, Shen H, Chang C, Hau E, Cesare A. Ablative Dose Radiation Induces Distinct Waves of Cell Death Dependent on Cell Cycle Phase via DNA Repair Pathway Choice. Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2022.07.1799] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
24
|
Yu Y, Dong W, Shi Y, Wu R, Yu Q, Ye F, Zhou C, Dong X, Li X, Li Y, Li Z, Pan Y, Shen H, Wu D, Xu Z, Wu J, Xu N, Qin Y, Li J, Lu S. 313P A pool analysis of MET TKI SCC244 in NSCLC patients with MET overexpression. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.10.342] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/07/2022] Open
|
25
|
Chen Z, Meng C, Mai J, Liu Y, Li H, Shen H. An mRNA vaccine elicits STING-dependent antitumor immune responses. Acta Pharm Sin B 2022; 13:1274-1286. [PMID: 36970194 PMCID: PMC10031366 DOI: 10.1016/j.apsb.2022.11.013] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2022] [Revised: 09/13/2022] [Accepted: 09/28/2022] [Indexed: 11/19/2022] Open
Abstract
Lipid-formulated RNA vaccines have been widely used for disease prevention and treatment, yet their mechanism of action and individual components contributing to such actions remain to be delineated. Here, we show that a therapeutic cancer vaccine composed of a protamine/mRNA core and a lipid shell is highly potent in promoting cytotoxic CD8+ T cell responses and mediating anti-tumor immunity. Mechanistically, both the mRNA core and lipid shell are needed to fully stimulate the expression of type I interferons and inflammatory cytokines in dendritic cells. Stimulation of interferon-β expression is exclusively dependent on STING, and antitumor activity from the mRNA vaccine is significantly compromised in mice with a defective Sting gene. Thus, the mRNA vaccine elicits STING-dependent antitumor immunity.
Collapse
|
26
|
Adam A, Shi Q, Wang B, Zou J, Mai J, Osman SR, Wu W, Xie X, Aguilar PV, Bao X, Shi PY, Shen H, Wang T. A modified porous silicon microparticle potentiates protective systemic and mucosal immunity for SARS-CoV-2 subunit vaccine. Transl Res 2022; 249:13-27. [PMID: 35688318 PMCID: PMC9173827 DOI: 10.1016/j.trsl.2022.06.004] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/21/2022] [Revised: 05/30/2022] [Accepted: 06/02/2022] [Indexed: 11/28/2022]
Abstract
Development of optimal SARS-CoV-2 vaccines to induce potent, long-lasting immunity and provide cross-reactive protection against emerging variants remains a high priority. Here, we report that a modified porous silicon microparticle (mPSM) adjuvant to SARS-CoV-2 receptor-binding domain (RBD) vaccine activated dendritic cells and generated more potent and durable systemic humoral and type 1 helper T (Th) cell- mediated immune responses than alum-formulated RBD following parenteral vaccination, and protected mice from SARS-CoV-2 and Beta variant challenge. Notably, mPSM facilitated the uptake of SARS-CoV-2 RBD antigens by nasal and airway epithelial cells. Parenteral and intranasal prime and boost vaccinations with mPSM-RBD elicited stronger lung resident T and B cells and IgA responses compared to parenteral vaccination alone, which led to markedly diminished viral loads and inflammation in the lung following SARS-CoV-2 Delta variant challenge. Overall, our results suggest that mPSM is effective adjuvant for SARS-CoV-2 subunit vaccine in both systemic and mucosal vaccinations.
Collapse
Key Words
- mpsm, modified porous silicon microparticle
- covid-19, coronavirus disease 2019
- rbd, receptor-binding domain
- sars-cov-2, severe acute respiratory syndrome coronavirus 2
- β-cov, betacoronavirus
- e, envelope
- m, membrane
- n, nucleocapsid
- hace2, human angiotensin-converting enzyme 2
- nabs, neutralizing antibodies
- dc, dendritic cell
- th1, t helper 1
- cpg, cytosine guanosine dinucleotide
- cgamp, cyclic gamp
- bm, bone marrow
- i.p., intraperitoneally
- i.d., intradermally
- i.m., or intramuscularly
- tmb, tetramethylbenzidine
- pbs-t, phosphate-buffered saline containing tween-20
- bal, bronchoalveolar lavage
- hrp, horseradish peroxidase
- elisa, enzyme-linked immunosorbent assay
- elispot, enzyme-linked immune absorbent spot
- sfc, spot-forming cells
- ics, intracellular cytokine staining
- moi, multiplicity of infection
- apc, antigen presenting cells
- mbc, memory b cell
- asc, antibody secreting cells
- prnt, plaque reduction neutralization test
- saec, small airway epithelial cells
- nalt, nasal-associated lymphoid tissue
- ade, antibody-dependent enhancement
- q-pcr, quantitative pcr
Collapse
Affiliation(s)
- Awadalkareem Adam
- Department of Microbiology & Immunology, University of Texas Medical Branch, Galveston, Texas
| | - Qing Shi
- Department of Nanomedicine, Houston Methodist Academic Institute, Houston, Texas
| | - Binbin Wang
- Department of Microbiology & Immunology, University of Texas Medical Branch, Galveston, Texas
| | - Jing Zou
- Department of Biochemistry & Molecular Biology, University of Texas Medical Branch, Galveston, Texas
| | - Junhua Mai
- Department of Nanomedicine, Houston Methodist Academic Institute, Houston, Texas
| | - Samantha R Osman
- Department of Microbiology & Immunology, University of Texas Medical Branch, Galveston, Texas
| | - Wenzhe Wu
- Department of Pediatrics, The University of Texas Medical Branch, Galveston, Texas
| | - Xuping Xie
- Department of Biochemistry & Molecular Biology, University of Texas Medical Branch, Galveston, Texas
| | - Patricia V Aguilar
- Department of Pathology, University of Texas Medical Branch, Galveston, Texas; Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, Texas; Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, Texas
| | - Xiaoyong Bao
- Department of Pediatrics, The University of Texas Medical Branch, Galveston, Texas; Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, Texas
| | - Pei-Yong Shi
- Department of Biochemistry & Molecular Biology, University of Texas Medical Branch, Galveston, Texas; Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, Texas; Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, Texas
| | - Haifa Shen
- Department of Nanomedicine, Houston Methodist Academic Institute, Houston, Texas; Innovative Therapeutic Program, Houston Methodist Cancer Center, Houston, Texas; ImmunoQ Therapeutics, Houston, Texas.
| | - Tian Wang
- Department of Microbiology & Immunology, University of Texas Medical Branch, Galveston, Texas; Department of Pathology, University of Texas Medical Branch, Galveston, Texas; Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, Texas; Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, Texas
| |
Collapse
|
27
|
Liu YT, Hu YY, Shen H, Liu S. [Research progress on screen exposure and negative emotions in adolescents]. Zhonghua Er Ke Za Zhi 2022; 60:1089-1092. [PMID: 36207863 DOI: 10.3760/cma.j.cn112140-20220328-00250] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/16/2023]
Affiliation(s)
- Y T Liu
- School of Public Health, Hangzhou Medical College, Hangzhou 310000, China
| | - Y Y Hu
- School of Public Health, Hangzhou Medical College, Hangzhou 310000, China
| | - H Shen
- School of Public Health, Hangzhou Medical College, Hangzhou 310000, China
| | - S Liu
- School of Public Health, Hangzhou Medical College, Hangzhou 310000, China
| |
Collapse
|
28
|
Xu T, Shen H, Lu B, Wei C, Wang Z. EP08.02-153 The Efficacy and Safety of EGFR-TKIs plus Anlotinib in Maintenance Therapy for Oligoprogressive Advanced or Metastatic EGFR Mutant NSCLC. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.836] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
29
|
Rodriguez-Aguayo C, Bayraktar E, Ivan C, Aslan B, Mai J, He G, Mangala LS, Jiang D, Nagaraja AS, Ozpolat B, Chavez-Reyes A, Ferrari M, Mitra R, Siddik ZH, Shen H, Yang X, Sood AK, Lopez-Berestein G. Corrigendum to “PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis” [EBioMedicine 40 (2019) 290-304]. EBioMedicine 2022; 83:104194. [PMID: 35914489 PMCID: PMC9340498 DOI: 10.1016/j.ebiom.2022.104194] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
Affiliation(s)
- Cristian Rodriguez-Aguayo
- Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | - Emine Bayraktar
- Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Medical Biology, Faculty of Medicine, University of Gaziantep, Gaziantep 27310, Turkey
| | - Cristina Ivan
- Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | - Burcu Aslan
- Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | - Junhua Mai
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA
| | - Guangan He
- Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | - Lingegowda S Mangala
- Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | - Dahai Jiang
- Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | - Archana S Nagaraja
- Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | - Bulent Ozpolat
- Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | - Arturo Chavez-Reyes
- Centro de Investigación y Estudios Avanzados del IPN, Unidad Monterrey, Apodaca, NL, CP. 66600, Mexico
| | - Mauro Ferrari
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA
| | - Rahul Mitra
- Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | - Zahid H Siddik
- Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | - Haifa Shen
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA
| | - Xianbin Yang
- AM Biotechnologies LLC, 12521 Gulf Freeway, Houston, TX 77034, USA
| | - Anil K Sood
- Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | - Gabriel Lopez-Berestein
- Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
| |
Collapse
|
30
|
Delfanti G, Cortesi F, Perini A, Antonini G, Azzimonti L, de Lalla C, Garavaglia C, Squadrito ML, Fedeli M, Consonni M, Sesana S, Re F, Shen H, Dellabona P, Casorati G. TCR-engineered iNKT cells induce robust antitumor response by dual targeting cancer and suppressive myeloid cells. Sci Immunol 2022; 7:eabn6563. [PMID: 35984893 DOI: 10.1126/sciimmunol.abn6563] [Citation(s) in RCA: 14] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
Adoptive immunotherapy with T cells engineered with tumor-specific T cell receptors (TCRs) holds promise for cancer treatment. However, suppressive cues generated in the tumor microenvironment (TME) can hinder the efficacy of these therapies, prompting the search for strategies to overcome these detrimental conditions and improve cellular therapeutic approaches. CD1d-restricted invariant natural killer T (iNKT) cells actively participate in tumor immunosurveillance by restricting suppressive myeloid populations in the TME. Here, we showed that harnessing iNKT cells with a second TCR specific for a tumor-associated peptide generated bispecific effectors for CD1d- and major histocompatibility complex (MHC)-restricted antigens in vitro. Upon in vivo transfer, TCR-engineered iNKT (TCR-iNKT) cells showed the highest efficacy in restraining the progression of multiple tumors that expressed the cognate antigen compared with nontransduced iNKT cells or CD8+ T cells engineered with the same TCR. TCR-iNKT cells achieved robust cancer control by simultaneously modulating intratumoral suppressive myeloid populations and killing malignant cells. This dual antitumor function was further enhanced when the iNKT cell agonist α-galactosyl ceramide (α-GalCer) was administered as a therapeutic booster through a platform that ensured controlled delivery at the tumor site, named multistage vector (MSV). These preclinical results support the combination of tumor-redirected TCR-iNKT cells and local α-GalCer boosting as a potential therapy for patients with cancer.
Collapse
Affiliation(s)
- Gloria Delfanti
- Experimental Immunology Unit, Division of Immunology, Transplantation and Infectious Diseases, San Raffaele Scientific Institute, Milan 20132, Italy
| | - Filippo Cortesi
- Experimental Immunology Unit, Division of Immunology, Transplantation and Infectious Diseases, San Raffaele Scientific Institute, Milan 20132, Italy
| | - Alessandra Perini
- Experimental Immunology Unit, Division of Immunology, Transplantation and Infectious Diseases, San Raffaele Scientific Institute, Milan 20132, Italy
| | - Gaia Antonini
- Experimental Immunology Unit, Division of Immunology, Transplantation and Infectious Diseases, San Raffaele Scientific Institute, Milan 20132, Italy
| | | | - Claudia de Lalla
- Experimental Immunology Unit, Division of Immunology, Transplantation and Infectious Diseases, San Raffaele Scientific Institute, Milan 20132, Italy
| | - Claudio Garavaglia
- Experimental Immunology Unit, Division of Immunology, Transplantation and Infectious Diseases, San Raffaele Scientific Institute, Milan 20132, Italy
| | - Mario L Squadrito
- Targeted Cancer Gene Therapy Unit, San Raffaele Telethon Institute for Gene Therapy (SR-TIGET), Milan 20132, Italy
| | - Maya Fedeli
- Experimental Immunology Unit, Division of Immunology, Transplantation and Infectious Diseases, San Raffaele Scientific Institute, Milan 20132, Italy
| | - Michela Consonni
- Experimental Immunology Unit, Division of Immunology, Transplantation and Infectious Diseases, San Raffaele Scientific Institute, Milan 20132, Italy
| | - Silvia Sesana
- BioNanoMedicine Center NANOMIB, School of Medicine and Surgery, University of Milano-Bicocca, 20854 Monza, Italy
| | - Francesca Re
- BioNanoMedicine Center NANOMIB, School of Medicine and Surgery, University of Milano-Bicocca, 20854 Monza, Italy
| | - Haifa Shen
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA
| | - Paolo Dellabona
- Experimental Immunology Unit, Division of Immunology, Transplantation and Infectious Diseases, San Raffaele Scientific Institute, Milan 20132, Italy
| | - Giulia Casorati
- Experimental Immunology Unit, Division of Immunology, Transplantation and Infectious Diseases, San Raffaele Scientific Institute, Milan 20132, Italy
| |
Collapse
|
31
|
Yang X, Shen H, Li Q, Dai Z, Yang R, Huang G, Chen R, Wang F, Song J, Hua H. [Interference of P2X4 receptor expression in tumor-associated macrophages suppresses migration and invasion of glioma cells]. Nan Fang Yi Ke Da Xue Xue Bao 2022; 42:658-664. [PMID: 35673908 DOI: 10.12122/j.issn.1673-4254.2022.05.05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
OBJECTIVE To investigate the effect of interference of P2X4 receptor expression in tumor-associated macrophages (TAMs) on invasion and migration of glioma cells. METHODS C57BL/6 mouse models bearing gliomas in the caudate nucleus were examined for glioma pathology with HE staining and expressions of Iba-1 and P2X4 receptor with immunofluorescence assay. RAW264.7 cells were induced into TAMs using conditioned medium from GL261 cells, and the changes in mRNA expressions of macrophage polarization-related markers and the mRNA and protein expressions of P2X4 receptor were detected with RT-qPCR and Western blotting. The effect of siRNA-mediated P2X4 interference on IL-1β and IL-18 mRNA and protein expressions in the TAMs was detected with RT-qPCR and Western blotting. GL261 cells were cultured in the conditioned medium from the transfected TAMs, and the invasion and migration abilities of the cells were assessed with Transwell invasion and migration experiment. RESULTS The glioma tissues from the tumor-bearing mice showed a significantly greater number of Iba-1-positive cells, where an obviously increased P2X4 receptor expression was detected (P=0.001), than the brain tissues of the control mice (P < 0.001). The M2 macrophage markers (Arg-1 and IL-10) and M1 macrophage markers (iNOS and TNF-α) were both significantly up-regulated in the TAMs derived from RAW264.7 cells (all P < 0.01), but the up-regulation of the M2 macrophage markers was more prominent; the expression levels of P2X4 receptor protein and mRNA were both increased in the TAMs (P < 0.05). Interference of P2X4 receptor expression significantly lowered the mRNA(P < 0.01)and protein (P < 0.01, P < 0.05)expression levels of IL-1β and IL-18 in the TAMs and obviously inhibited the ability of the TAMs to promote invasion and migration of the glioma cells (P < 0.05). CONCLUSION Interference of P2X4 receptor in the TAMs suppresses the migration and invasion of glioma cells possibly by lowering the expressions of IL-1β and IL-18.
Collapse
Affiliation(s)
- X Yang
- Department of Pathology and Pathophysiology, Kunming Medical University, Kunming 650500, China
| | - H Shen
- Department of Pathology, Zhaotong First People's Hospital, Zhaotong 657099, China
| | - Q Li
- Clinic Skill Center, Kunming Medical University, Kunming 650500, China
| | - Z Dai
- Institute of Stomatology, Affiliated Stomatology Hospital, Kunming Medical University, Kunming 650500, China
| | - R Yang
- Institute of Stomatology, Affiliated Stomatology Hospital, Kunming Medical University, Kunming 650500, China
| | - G Huang
- Institute of Stomatology, Affiliated Stomatology Hospital, Kunming Medical University, Kunming 650500, China
| | - R Chen
- Institute of Stomatology, Affiliated Stomatology Hospital, Kunming Medical University, Kunming 650500, China
| | - F Wang
- Department of Pathology and Pathophysiology, Kunming Medical University, Kunming 650500, China
| | - J Song
- Electron Microscope, Kunming Medical University, Kunming 650500, China
| | - H Hua
- Department of Pathology and Pathophysiology, Kunming Medical University, Kunming 650500, China
| |
Collapse
|
32
|
Chen J, Yuan Y, Peng W, Tang Y, Chen X, Wang Y, Shen H, Li R. [Application of three-dimensional visualization technique in laparoscopic D3 radical resection of right colon cancer]. Nan Fang Yi Ke Da Xue Xue Bao 2022; 42:760-765. [PMID: 35673922 DOI: 10.12122/j.issn.1673-4254.2022.05.19] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
OBJECTIVE To explore the clinical value of three-dimensional (3D) visualization technique in laparoscopic D3 radical resection of right colon cancer. METHODS We retrospectively analyzed the clinical data of 73 patients with right colon cancer undergoing laparoscopic D3 radical operation in our hospital between May, 2019 and March, 2021. Among these patients, 41 underwent enhanced CT examination with 3D visualization reconstruction to guide the actual operation, and 32 underwent enhanced CT examination only before the operation (control group). In 3D visualization group, we examined the coincidence rate between the 3D visualization model and the findings in surgical exploration of the anatomy and variations of the main blood vessels, supplying vessels of the tumor, and the tumor location, and the coincidence rate between the actual surgical plan for D3 radical resection of right colon cancer and the plan formulated based on the 3D model. The operative time, estimated blood loss, unexpected injury of blood vessels, number of harvested lymph nodes, mean time of the first flatus, complications, postoperative hospital stay and postoperative drainage volume were compared between the two groups. RESULTS The operative time was significantly shorter in 3D visualization group than in the control group (P < 0.05). The volume of blood loss, proportion of unexpected injury of blood vessel, the number of harvested lymph nodes, time of the first flatus, proportion of complications, postoperative hospital stay and postoperative drainage volume did not differ significantly between the two groups (P > 0.05). In the 3D visualization group, the 3D visualization model clearly displayed the shape and direction of the colon, the location of the tumor, the anatomy and variation of the main blood vessels and the blood vessels supplying the cancer, and showed a coincidence rate of 100% with the findings by surgical exploration. The surgical plan for D3 radical resection of right colon cancer was formulated based on the 3D model also showed a coincidence rate of 100% with the actual surgical plan. CONCLUSION The 3D visualization reconstruction technique allows clear visualization the supplying arteries of the tumor and their variations to improve the efficiency, safety and accuracy of laparoscopic D3 radical resection of right colon cancer.
Collapse
Affiliation(s)
- J Chen
- Department of Gastrointestinal Surgery, Dongguan People's Hospital Affiliated to Southern Medical University, Dongguan 523059, China
| | - Y Yuan
- Department of Gastroenterology, Dongguan People's Hospital Affiliated to Southern Medical University, Dongguan 523059, China
| | - W Peng
- Department of Gastrointestinal Surgery, Dongguan People's Hospital Affiliated to Southern Medical University, Dongguan 523059, China
| | - Y Tang
- Department of Gastrointestinal Surgery, Dongguan People's Hospital Affiliated to Southern Medical University, Dongguan 523059, China
| | - X Chen
- Department of Gastrointestinal Surgery, Dongguan People's Hospital Affiliated to Southern Medical University, Dongguan 523059, China
| | - Y Wang
- Department of Gastrointestinal Surgery, Dongguan People's Hospital Affiliated to Southern Medical University, Dongguan 523059, China
| | - H Shen
- Department of Radiology, Dongguan People's Hospital Affiliated to Southern Medical University, Dongguan 523059, China
| | - R Li
- Department of Gastrointestinal Surgery, Dongguan People's Hospital Affiliated to Southern Medical University, Dongguan 523059, China
| |
Collapse
|
33
|
Tian S, Welte T, Mai J, Liu Y, Ramirez M, Shen H. Identification of an Aptamer With Binding Specificity to Tumor-Homing Myeloid-Derived Suppressor Cells. Front Pharmacol 2022; 12:752934. [PMID: 35126104 PMCID: PMC8814529 DOI: 10.3389/fphar.2021.752934] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2021] [Accepted: 12/31/2021] [Indexed: 11/23/2022] Open
Abstract
Myeloid-derived suppressor cells (MDSCs) play a critical role in tumor growth and metastasis. Since they constantly infiltrate into the tumor tissue, these cells are considered as an ideal carrier for tumor-targeted drug delivery. We recently identified a DNA-based thioaptamer (T1) with tumor accumulating activity, demonstrated its potential on tumor targeting and drug delivery. In the current study, we have carried out structure-activity relationship analysis to further optimize the aptamer. In the process, we have identified a sequence-modified aptamer (M1) that shows an enhanced binding affinity to MDSCs over the parental T1 aptamer. In addition, M1 can penetrate into the tumor tissue more effectively by hitchhiking on MDSCs. Taken together, we have identified a new reagent for enhanced tumor-targeted drug delivery.
Collapse
Affiliation(s)
- Shaohui Tian
- Department of Nanomedicine, Houston Methodist Academic Institute, Houston, TX, United States,Department of Gastrointestinal Surgery, The Third Xiangya Hospital of Central South University, Changsha, China
| | - Thomas Welte
- Department of Nanomedicine, Houston Methodist Academic Institute, Houston, TX, United States
| | - Junhua Mai
- Department of Nanomedicine, Houston Methodist Academic Institute, Houston, TX, United States
| | - Yongbin Liu
- Department of Nanomedicine, Houston Methodist Academic Institute, Houston, TX, United States
| | - Maricela Ramirez
- Department of Nanomedicine, Houston Methodist Academic Institute, Houston, TX, United States
| | - Haifa Shen
- Department of Nanomedicine, Houston Methodist Academic Institute, Houston, TX, United States,Weill Cornell Medical College, White Plains, NY, United States,*Correspondence: Haifa Shen,
| |
Collapse
|
34
|
Liu X, Mai J, Meng C, Spiegel AJ, Wei W, Shen H. Antitumor Immunity from Abdominal Flap-Embedded Therapeutic Cancer Vaccine. Int J Nanomedicine 2022; 17:203-212. [PMID: 35046655 PMCID: PMC8760982 DOI: 10.2147/ijn.s341394] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2021] [Accepted: 12/26/2021] [Indexed: 11/23/2022] Open
Affiliation(s)
- Xiaoling Liu
- Department of Nanomedicine, Houston Methodist Academic Institute, Houston, TX, 77030, USA
- Department of Breast and Thyroid Surgery, Peking University Shenzhen Hospital, Shenzhen, Guangdong, 518036, People’s Republic of China
| | - Junhua Mai
- Department of Nanomedicine, Houston Methodist Academic Institute, Houston, TX, 77030, USA
| | - Chaoyang Meng
- Department of Nanomedicine, Houston Methodist Academic Institute, Houston, TX, 77030, USA
| | - Aldona J Spiegel
- Institute for Reconstructive Surgery, Houston Methodist Hospital, Weill Cornell Medicine, Houston, TX, USA
| | - Wei Wei
- Department of Breast and Thyroid Surgery, Peking University Shenzhen Hospital, Shenzhen, Guangdong, 518036, People’s Republic of China
| | - Haifa Shen
- Department of Nanomedicine, Houston Methodist Academic Institute, Houston, TX, 77030, USA
- Correspondence: Haifa Shen Department of Nanomedicine, Houston Methodist Academic Institute, Houston, TX, 77030, USATel +1 713-441-7321 Email
| |
Collapse
|
35
|
Chen YH, Shen ZY, Huang HY, Yu YS, Ye WX, Hua F, Hu YQ, Yang BW, Shen H. [Comparison of early outcome between one-stage hybrid technique and frozen elephant thunk technique in the treatment of Stanford A aortic dissection involving the arch]. Zhonghua Yi Xue Za Zhi 2021; 101:3955-3960. [PMID: 34954998 DOI: 10.3760/cma.j.cn112137-20210531-01246] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To analyze the early outcome of one-stage hybrid technique in the treatment of Stanford type-A aortic dissection involving the arch and compare its therapeutic efficacy with the classical frozen elephant trunk technique (FET). Methods: A total of 106 patients with Stanford type-A aortic dissection involving the arch in Department of Cardiac and Vascular Surgery, 1st Affiliated Hospital of Soochow University from October 2015 to October 2019 was collected. All patients in this group were treated with one-stage hybrid technique (modified arch debranching technique) without deep hypothermia circulation. Meanwhile, 30 patients with Stanford type A dissection involving the arch who underwent FET from January 2014 to September 2015 were collected. The therapeutic effects of the two surgical methods were analyzed and compared. Results: The age [M (Q1, Q3)] of 106 patients in hybrid group was 49.0 (40.0, 55.0) years, including 89 males and 17 females. The age [M(Q1, Q3)] of 30 patients in FET group was 49.5 (41.5, 65.3) years, including 24 males and 6 females. The time [M(Q1, Q3)] of using ventilator in hybrid group was 56.0 (38.0, 72.0) h, which was shorter than 127.0 (92.0, 145.0) h in FET group (P<0.001). The incidence of cerebral infarction in hybrid group was 2.8% (3 cases), which was lower than 13.3% (4 cases) in FET group (P=0.042); the incidence of postoperative renal insufficiency in hybrid group was 7.5% (8 cases), which was lower than 23.3% (7 cases) in FET group (P=0.023); the ICU time [M (Q1, Q3)] in hybrid group was 8.0 (6.0, 10.0) d, which was shorter than 14.0 (8.3, 24.0) d in FET group (P<0.001). Conclusion: Compared with FET, one-stage hybrid technology is safer and more effective in the treatment of Stanford type A aortic dissection involving the arch. Its short-term therapeutic efficacy appears good.
Collapse
Affiliation(s)
- Y H Chen
- Department of Cardiac and Vascular Surgery, 1st Affiliated Hospital of Soochow University, Suzhou 215006, China
| | - Z Y Shen
- Department of Cardiac and Vascular Surgery, 1st Affiliated Hospital of Soochow University, Suzhou 215006, China
| | - H Y Huang
- Department of Cardiac and Vascular Surgery, 1st Affiliated Hospital of Soochow University, Suzhou 215006, China
| | - Y S Yu
- Department of Cardiac and Vascular Surgery, 1st Affiliated Hospital of Soochow University, Suzhou 215006, China
| | - W X Ye
- Department of Cardiac and Vascular Surgery, 1st Affiliated Hospital of Soochow University, Suzhou 215006, China
| | - F Hua
- Department of Cardiac and Vascular Surgery, 1st Affiliated Hospital of Soochow University, Suzhou 215006, China
| | - Y Q Hu
- Department of Cardiac and Vascular Surgery, 1st Affiliated Hospital of Soochow University, Suzhou 215006, China
| | - B W Yang
- Department of Cardiac and Vascular Surgery, 1st Affiliated Hospital of Soochow University, Suzhou 215006, China
| | - H Shen
- Department of Cardiac and Vascular Surgery, 1st Affiliated Hospital of Soochow University, Suzhou 215006, China
| |
Collapse
|
36
|
Zhen Z, Dong F, Shen H, Wang QG, Yang L, Hu J. MiR-524 inhibits cell proliferation and induces cell apoptosis in thyroid cancer via targeting SPAG9. Eur Rev Med Pharmacol Sci 2021; 25:7192. [PMID: 34919215 DOI: 10.26355/eurrev_202112_27408] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
The article "MiR-524 inhibits cell proliferation and induces cell apoptosis in thyroid cancer via targeting SPAG9", by Z. Zhen, F. Dong, H. Shen, Q.-G. Wang, L. Yang, J. Hu, published in Eur Rev Med Pharmacol Sci 2018; 22 (12): 3812-3818-DOI: 10.26355/eurrev_201806_15265-PMID: 29949157, has been retracted by the authors due to some unrepeated data in their current research. The Publisher apologizes for any inconvenience this may cause. https://www.europeanreview.org/article/15265.
Collapse
Affiliation(s)
- Z Zhen
- Department of Otolaryngology, Head and Neck Surgery, Peking University First Hospital, Beijing, China
| | | | | | | | | | | |
Collapse
|
37
|
Wu Z, Zhu L, Mai J, Shen H, Xu R. Rad51 Silencing with siRNA Delivered by Porous Silicon-Based Microparticle Enhances the Anti-Cancer Effect of Doxorubicin in Triple-Negative Breast Cancer. J Biomed Nanotechnol 2021; 17:2351-2363. [PMID: 34974858 DOI: 10.1166/jbn.2021.3198] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Due to its high heterogeneity and aggressiveness, cytotoxic chemotherapy is still a mainstay treatment for triple negative breast cancer. Unfortunately, the above mentioned has not significantly ameliorated TNBC patients and induces drug resistance. Exploring the mechanisms underlying the chemotherapy sensitivity of TNBC and developing novel sensitization strategies are promising approaches for improving the prognosis of patients. Rad51, a key regulator of DNA damage response pathway, repairs DNA damage caused by genotoxic agents through "homologous recombination repair." Therefore, Rad51 inhibition may increase TNBC cell sensitivity to anticancer agents. Based on these findings, we first designed Rad51 siRNA to inhibit the Rad51 protein expression in vitro and evaluated the sensitivity of TNBC cells to doxorubicin. Subsequently, we constructed discoidal porous silicon microparticles (pSi) and encapsulated discoidal 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) liposomes/siRad51 (PS-DOPC/siRad51) to explore the synergistic antitumor effects of siRad51 and doxorubicin on two mouse models of TNBC in vivo. Our in vitro studies indicated that siRad51 enhanced the efficacy of DOX chemotherapy and significantly suppressed TNBC cell proliferation and metastasis. This effect was related to apoptosis induction and epithelial to mesenchymal transition (EMT) inhibition. siRad51 altered the expression of apoptosis- and EMT-related proteins. In orthotopic and lung metastasis xenograft models, the administration of PS-DOPC/siRad51 in combination with DOX significantly alleviated the primary tumor burden and lung metastasis, respectively. Our current studies present an efficient strategy to surmount chemotherapy resistance in TNBC through microvector delivery of siRad51.
Collapse
Affiliation(s)
- Zeliang Wu
- Department of Pharmacology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, People's Republic of China
| | - Lin Zhu
- Department of Pharmacy, Wuhan Wuchang Hospital, Wuhan University of Science and Technology, Wuhan 430061, People's Republic of China
| | - Junhua Mai
- Department of Nanomedicine, Houston Methodist Research Institute, 6670 Bertner Ave, Houston 77030, USA
| | - Haifa Shen
- Department of Nanomedicine, Houston Methodist Research Institute, 6670 Bertner Ave, Houston 77030, USA
| | - Rong Xu
- Department of Pharmacology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, People's Republic of China
| |
Collapse
|
38
|
Adam A, Shi Q, Wang B, Zou J, Mai J, Osman SR, Wu W, Xie X, Aguilar PV, Bao X, Shi PY, Shen H, Wang T. A modified porous silicon microparticle promotes mucosal delivery of SARS-CoV-2 antigen and induction of potent and durable systemic and mucosal T helper 1 skewed protective immunity. bioRxiv 2021. [PMID: 34845456 DOI: 10.1101/2021.11.22.469576] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
Development of optimal SARS-CoV-2 vaccines to induce potent, long-lasting immunity and provide cross-reactive protection against emerging variants remains a high priority. Here, we report that a modified porous silicon microparticle (mPSM)-adjuvanted SARS-CoV-2 receptor-binding domain (RBD) vaccine activated dendritic cells and generated more potent and durable SARS-CoV-2-specific systemic humoral and type 1 helper T (Th) cell-mediated immune responses than alum-formulated RBD following parenteral vaccination, and protected mice from SARS-CoV-2 and Beta variant infection. mPSM facilitated the uptake of SARS-CoV-2 RBD antigens by nasal and airway epithelial cells. Parenteral and intranasal prime and boost vaccinations with mPSM-RBD elicited potent systemic and lung resident memory T and B cells and SARS-CoV-2 specific IgA responses, and markedly diminished viral loads and inflammation in the lung following SARS-CoV-2 Delta variant infection. Our results suggest that mPSM can serve as potent adjuvant for SARS-CoV-2 subunit vaccine which is effective for systemic and mucosal vaccination.
Collapse
|
39
|
Welte T, Mai J, Zhang Z, Tian S, Zhang G, Xu Y, Zhang L, Chen SS, Wang T, Shen H. A heparan-sulfate-bearing syndecan-1 glycoform is a distinct surface marker for intra-tumoral myeloid-derived suppressor cells. iScience 2021; 24:103349. [PMID: 34825135 PMCID: PMC8603209 DOI: 10.1016/j.isci.2021.103349] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2021] [Revised: 09/17/2021] [Accepted: 10/22/2021] [Indexed: 11/19/2022] Open
Abstract
Myeloid-derived suppressor cells (MDSCs) infiltrate cancer tissue, promote tumor growth, and are associated with resistance to cancer therapies. However, there is no practical approach available to distinguish MDSCs from mature counterparts inside tumors. Here, we show that a recently isolated thioaptamer probe (T1) binds to MDSC subsets in colorectal and pancreatic tumors with high specificity. Whole transcriptome and functional analysis revealed that T1-binding cells contain polymorphonuclear (PMN)-MDSCs characterized by several immunosuppression pathways, ROS production, and T cell suppression activity, whereas T1-non-binding PMNs were mature and nonsuppressive. We identified syndecan-1 as the T1-interacting protein on MDSCs and chronic myelogenous leukemia K562 cell line. Heparan sulfate chains were essential in T1-binding. Inside tumors PMN-MDSCs expressed heparan sulfate biogenesis enzymes at higher levels. Tumor-cell-derived soluble factor(s) enhanced MDSCs' affinity for T1. Overall, we uncovered heparan-sulfate-dependent MDSC modulation in the tumor microenvironment and identified T1 as tool preferentially targeting tumor-promoting myeloid cell subsets.
Collapse
Affiliation(s)
- Thomas Welte
- Department of Nanomedicine, Houston Methodist Academic Institute, Houston, TX 77030, USA
| | - Junhua Mai
- Department of Nanomedicine, Houston Methodist Academic Institute, Houston, TX 77030, USA
| | - Zhe Zhang
- Department of Nanomedicine, Houston Methodist Academic Institute, Houston, TX 77030, USA
| | - Shaohui Tian
- Department of Nanomedicine, Houston Methodist Academic Institute, Houston, TX 77030, USA
| | - Guodong Zhang
- Department of Nanomedicine, Houston Methodist Academic Institute, Houston, TX 77030, USA
| | - Yitian Xu
- Center for Immunotherapy Research, Houston Methodist Academic Institute, Houston, TX 77030, USA
| | - Licheng Zhang
- Center for Immunotherapy Research, Houston Methodist Academic Institute, Houston, TX 77030, USA
| | - Shu-shia Chen
- Center for Immunotherapy Research, Houston Methodist Academic Institute, Houston, TX 77030, USA
| | - Tian Wang
- Department of Microbiology & Immunology, The University of Texas Medical Branch, 301 University Boulevard, Galveston, TX 77555, USA
| | - Haifa Shen
- Department of Nanomedicine, Houston Methodist Academic Institute, Houston, TX 77030, USA
- Innovative Therapeutic Program, Houston Methodist Cancer Center, Houston, TX 77030, USA
- Department of Cell and Developmental Biology, Weill Cornell Medicine, New York, NY 10065, USA
- Corresponding author
| |
Collapse
|
40
|
Hinkle L, Liu Y, Meng C, Chen Z, Mai J, Zhang L, Xu Y, Pan PY, Chen SH, Shen H. The Sympathetic Nervous System Modulates Cancer Vaccine Activity through Monocyte-Derived Cells. J Immunol 2021; 207:3131-3140. [PMID: 34772699 DOI: 10.4049/jimmunol.2100719] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/21/2021] [Accepted: 10/05/2021] [Indexed: 11/19/2022]
Abstract
The sympathetic nervous system (SNS) is an important regulator of immune cell function during homeostasis and states of inflammation. Recently, the SNS has been found to bolster tumor growth and impair the development of antitumor immunity. However, it is unclear whether the SNS can modulate APC function. Here, we investigated the effects of SNS signaling in murine monocyte-derived macrophages (moMФ) and dendritic cells (DCs) and further combined the nonspecific β-blocker propranolol with a peptide cancer vaccine for the treatment of melanoma in mice. We report that norepinephrine treatment dramatically altered moMФ cytokine production, whereas DCs were unresponsive to norepinephrine and critically lack β2-adrenergic receptor expression. In addition, we show that propranolol plus cancer vaccine enhanced peripheral DC maturation, increased the intratumor proportion of effector CD8+ T cells, and decreased the presence of intratumor PD-L1+ myeloid-derived suppressor cells. Furthermore, this combination dramatically reduced tumor growth compared with vaccination alone. Taken together, these results offer insights into the cell-specific manner by which the SNS regulates the APC immune compartment and provide strong support for the use of propranolol in combination with cancer vaccines to improve patient response rates and survival.
Collapse
Affiliation(s)
- Louis Hinkle
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX.,Texas A&M Health Science Center, Bryan, TX
| | - Yongbin Liu
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX
| | - Chaoyang Meng
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX.,Xiangya Hospital of Central South University, Changsha, Hunan, China
| | - Zhe Chen
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX.,Xiangya Hospital of Central South University, Changsha, Hunan, China
| | - Junhua Mai
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX
| | - Licheng Zhang
- Center for Cancer Immunotherapy, Houston Methodist Research Institute, Houston, TX; and
| | - Yitian Xu
- Center for Cancer Immunotherapy, Houston Methodist Research Institute, Houston, TX; and
| | - Ping-Ying Pan
- Center for Cancer Immunotherapy, Houston Methodist Research Institute, Houston, TX; and.,Weill Cornell Medical College, New York, NY
| | - Shu-Hsia Chen
- Center for Cancer Immunotherapy, Houston Methodist Research Institute, Houston, TX; and.,Weill Cornell Medical College, New York, NY
| | - Haifa Shen
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX; .,Weill Cornell Medical College, New York, NY
| |
Collapse
|
41
|
Meng C, Chen Z, Mai J, Shi Q, Tian S, Hinkle L, Li J, Zhang Z, Ramirez M, Zhang L, Xu Y, Zhang J, Pan P, Chen S, Li H, Shen H. Virus-Mimic mRNA Vaccine for Cancer Treatment. Adv Ther (Weinh) 2021; 4:2100144. [PMID: 34901386 PMCID: PMC8646380 DOI: 10.1002/adtp.202100144] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2021] [Revised: 08/31/2021] [Indexed: 12/13/2022]
Abstract
An effective therapeutic cancer vaccine should be empowered with the capacity to overcome the immunosuppressive tumor microenvironment. Here, the authors describe a mRNA virus-mimicking vaccine platform that is comprised of a phospholipid bilayer encapsulated with a protein-nucleotide core consisting of antigen-encoding mRNA molecules, unmethylated CpG oligonucleotides and positively charged proteins. In cell culture, VLVP potently stimulated bone marrow-derived dendritic cells (BMDCs) to express inflammatory cytokines that facilitated dendritic cell (DC) maturation and promoted antigen processing and presentation. In tumor-bearing mice, VLVP treatment stimulated proliferation of antigen-specific CD8+T cells in the lymphatic organs and T cell infiltration into the tumor bed, resulting in potent anti-tumor immunity. Cytometry by time of flight (CyTOF) analysis revealed that VLVP treatment stimulated a 5-fold increase in tumor-associated CD8+DCs and a 4-fold increase in tumorinfiltrated CD8+T cells, with concurrent decreases in tumor-associated bone marrow-derived suppressor cells and arginase 1- expressing suppressive DCs. Finally, CpG oligonucleotide is an essential adjuvant for vaccine activity. Inclusion of CpG not only maximized vaccine activity but also prevented PD-1 expression in T cells, serving the dual roles as a potent adjuvant and a checkpoint blockade agent.
Collapse
Affiliation(s)
- Chaoyang Meng
- Department of NanomedicineHouston Methodist Academic InstituteHoustonTX77030USA
- Xiangya Hospital of Central South UniversityChangshaHunan410000China
- Present address:
Department of Hepatobiliary and Pancreatic Surgery, First Affiliated HospitalZhejiang University School of MedicineHangzhou310009China
| | - Zhe Chen
- Department of NanomedicineHouston Methodist Academic InstituteHoustonTX77030USA
- Xiangya Hospital of Central South UniversityChangshaHunan410000China
| | - Junhua Mai
- Department of NanomedicineHouston Methodist Academic InstituteHoustonTX77030USA
| | - Qing Shi
- Department of NanomedicineHouston Methodist Academic InstituteHoustonTX77030USA
| | - Shaohui Tian
- Department of NanomedicineHouston Methodist Academic InstituteHoustonTX77030USA
- Xiangya Hospital of Central South UniversityChangshaHunan410000China
| | - Louis Hinkle
- Department of NanomedicineHouston Methodist Academic InstituteHoustonTX77030USA
| | - Jun Li
- Department of NanomedicineHouston Methodist Academic InstituteHoustonTX77030USA
- Xiangya Hospital of Central South UniversityChangshaHunan410000China
| | - Zhe Zhang
- Department of NanomedicineHouston Methodist Academic InstituteHoustonTX77030USA
| | - Maricela Ramirez
- Department of NanomedicineHouston Methodist Academic InstituteHoustonTX77030USA
| | - Licheng Zhang
- Center for Immunotherapy ResearchHouston Methodist Academic InstituteHoustonTX77030USA
| | - Yitian Xu
- Center for Immunotherapy ResearchHouston Methodist Academic InstituteHoustonTX77030USA
| | - Jilu Zhang
- Center for Immunotherapy ResearchHouston Methodist Academic InstituteHoustonTX77030USA
| | - Ping‐Ying Pan
- Center for Immunotherapy ResearchHouston Methodist Academic InstituteHoustonTX77030USA
- Weill Cornell Medical CollegeNew YorkNY10065USA
| | - Shu‐Hsia Chen
- Center for Immunotherapy ResearchHouston Methodist Academic InstituteHoustonTX77030USA
- Weill Cornell Medical CollegeNew YorkNY10065USA
| | - Hangwen Li
- StemiRNA Therapeutics IncShanghai201206China
| | - Haifa Shen
- Department of NanomedicineHouston Methodist Academic InstituteHoustonTX77030USA
- Weill Cornell Medical CollegeNew YorkNY10065USA
| |
Collapse
|
42
|
Ge WX, Tan WL, Teng HY, Shen H, Han D, Xiao Y, Yin JY, Hu J. [Trajectories of body mass index Z-score and risk of high blood pressure in late adolescence in Suzhou children]. Zhonghua Liu Xing Bing Xue Za Zhi 2021; 42:1809-1816. [PMID: 34814616 DOI: 10.3760/cma.j.cn112338-20201130-01365] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/13/2023]
Abstract
Objective: To identify age and gender standardized body mass index among children and adolescents and explore their associations with high blood pressure (HBP) in late adolescence. Methods: The current study was based on the Health Promotion Program for Children and Adolescents, school-based surveillance successively conducted from 2012 to 2019 in Suzhou, China. A total of 11 812 children and adolescents aged 16-18 years, who had ≥4 examination records during 2012-2018 and were also involved in a surveillance program in 2019, were included. Latent class growth mixture modeling was used to identify the BMI-Z trajectories in different genders, and multivariate logistic regression was used to analyze the associations between different BMI-Z trajectories and risk of HBP in late adolescence. Results: Six distinct BMI-Z trajectories were determined for both genders:thin, slightly thin,standard, declining, overweight, and obese. Compared with the regular group, the obesity group had 94.0% (OR=1.94, 95%CI: 1.43-2.63) and 107.0% (OR=2.07, 95%CI: 1.33-3.22) increased risk of developing HBP in late adolescence in boys and girls, respectively. However, a neutral association was found between the descending group and HBP in late adolescence. Conclusions: Persistent obesity in children may increase the risk of HBP in their late adolescence. If an obese child restores normal weight before late adolescence, the risk of HBP may reduce.
Collapse
Affiliation(s)
- W X Ge
- School of Public Health, Soochow University, Suzhou 215006, China
| | - W L Tan
- School of Public Health, Soochow University, Suzhou 215006, China Suzhou Municipal Health Commission, Suzhou 215000, China
| | - H Y Teng
- School of Public Health, Soochow University, Suzhou 215006, China
| | - H Shen
- Suzhou Center for Disease Control and Prevention, Suzhou 215004, China
| | - D Han
- Suzhou Center for Disease Control and Prevention, Suzhou 215004, China
| | - Y Xiao
- School of Public Health, Soochow University, Suzhou 215006, China
| | - J Y Yin
- School of Public Health, Soochow University, Suzhou 215006, China
| | - J Hu
- Suzhou Center for Disease Control and Prevention, Suzhou 215004, China
| |
Collapse
|
43
|
Shen H, Sestier M, Beaulieu M, Soltani I, Hillani A, Matteau A, Mansour S, Potter B. ELIGIBILITY FOR ASPIRIN PLUS LOW-DOSE RIVAROXABAN AMONG CARDIOLOGY OUTPATIENTS IN AN ACADEMIC TERTIARY CARE CENTER. Can J Cardiol 2021. [DOI: 10.1016/j.cjca.2021.07.081] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
44
|
Zhou C, Wang Z, Sun Y, Cao L, Ma Z, Wu R, Yu Y, Yao W, Wang H, Chen J, Zhuang W, Cui J, Chen X, Lu Y, Shen H, Chen R, Xu X, Lu D, Wang J, Yang J. MA13.07 GEMSTONE-302: A Phase 3 Study of Platinum-Based Chemotherapy with Placebo or Sugemalimab, a PD-L1 mAb, for metastatic NSCLC. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.180] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
45
|
Shen H, Sestier M, Soltani I, Beaulieu M, Hillani A, Mansour S, Matteau A, Potter B. GASTROPROTECTION IN PATIENTS ON ANTITHROMBOTIC THERAPY: A QUALITY IMPROVEMENT STUDY. Can J Cardiol 2021. [DOI: 10.1016/j.cjca.2021.07.080] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
46
|
Zhou Q, Yang Y, Wang L, Chen X, Xu Q, Wang Q, Shen H, Xu Z, Zhang Y, Yan D, Peng Z, He Y, Wang Y, Li X, Ma X. Intra-couple discordance in preconception syphilis screening for both spouses: a national and population-based survey in China, 2013-2018. BJOG 2021; 129:313-321. [PMID: 34532971 DOI: 10.1111/1471-0528.16923] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/27/2021] [Indexed: 11/29/2022]
Abstract
OBJECTIVE The antenatal screening strategy remains inadequate for eliminating congenital syphilis. To further eliminate maternal fetal transmission, preconception syphilis screening is considered an option. In this study, we investigated syphilis seropositivity and intra-couple discordance among married couples planning a pregnancy in China to provide essential baseline evidence for preconception syphilis screening. DESIGN Population-based survey. SETTING National preconception registered data. POPULATION Married Chinese couples planning conception within 6 months between 2013 and 2018. METHODS Syphilis was screened using rapid plasma reagin (RPR); infection self-reporting and sociodemographic characteristics were collected through questionnaires and medical records, respectively. r 3.2.2 and arcgis 10.2 were used for statistical analyses and geographic mapping. MAIN OUTCOME MEASURES RPR seropositivity. RESULTS Among 31 955 041 couples, 29 737 172 (93.06%) had complete RPR results for both spouses; of those, 0.62% (186 100) were seropositive, with dramatic intra-couple discordance, with 0.33% positivity in wives, 0.24% positivity in husbands and 0.05% positivity in both spouses. Across time, both seropositivity and intra-couple discordance remained stable. Seropositivity in different regions varied significantly, with provincial rates ranging geographically from Tibet (0.8%) to Hebei (0.2%) (P < 0.05). Economic level was an independent factor for this regional variation, with seropositivity increasing as gross domestic product income decreased (P < 0.05). CONCLUSIONS Intra-couple discordance in seropositivity for syphilis is notable among couples, with a considerable rate of pre-existing syphilis before pregnancy. Thus, screening both spouses during integrated preconception health care is recommended for further eliminating maternal-fetal transmission. TWEETABLE ABSTRACT Intra-couple discordance in seropositivity for syphilis is notable among couples, with a considerable rate of pre-existing syphilis before pregnancy. Screening both spouses during integrated preconception health care is recommended to further eliminate maternal-fetal transmission.
Collapse
Affiliation(s)
- Q Zhou
- Obstetrics and Gynaecology Hospital of Fudan University, Shanghai, China.,Shanghai Key Laboratory of Female Reproductive Endocrine-Related Diseases, Shanghai, China.,Women's Health and Perinatology Research Group, Department of Clinical Medicine, UiT-The Arctic University of Norway, Tromsø, Norway
| | - Y Yang
- National Research Institute for Family Planning, Beijing, China.,National Human Genetic Resources Center, Beijing, China
| | - L Wang
- National Research Institute for Family Planning, Beijing, China.,Graduate School of Peking Union Medical College, Beijing, China.,School of Public Health, Institute for Epidemiology and Statistics, Lanzhou University, Lanzhou, China
| | - X Chen
- Obstetrics and Gynaecology Hospital of Fudan University, Shanghai, China
| | - Q Xu
- National Research Institute for Family Planning, Beijing, China.,Graduate School of Peking Union Medical College, Beijing, China
| | - Q Wang
- Department of Maternal and Child Health, National Health and Family Planning Commission of the People's Republic of China, Beijing, China
| | - H Shen
- Department of Maternal and Child Health, National Health and Family Planning Commission of the People's Republic of China, Beijing, China
| | - Z Xu
- Department of Maternal and Child Health, National Health and Family Planning Commission of the People's Republic of China, Beijing, China
| | - Y Zhang
- Department of Maternal and Child Health, National Health and Family Planning Commission of the People's Republic of China, Beijing, China
| | - D Yan
- Department of Maternal and Child Health, National Health and Family Planning Commission of the People's Republic of China, Beijing, China
| | - Z Peng
- National Research Institute for Family Planning, Beijing, China.,National Human Genetic Resources Center, Beijing, China
| | - Y He
- National Research Institute for Family Planning, Beijing, China.,National Human Genetic Resources Center, Beijing, China
| | - Y Wang
- National Research Institute for Family Planning, Beijing, China.,National Human Genetic Resources Center, Beijing, China
| | - X Li
- Obstetrics and Gynaecology Hospital of Fudan University, Shanghai, China.,Shanghai Key Laboratory of Female Reproductive Endocrine-Related Diseases, Shanghai, China.,Institute of Biomedical Sciences, Fudan University, Shanghai, China
| | - X Ma
- National Research Institute for Family Planning, Beijing, China.,National Human Genetic Resources Center, Beijing, China.,Graduate School of Peking Union Medical College, Beijing, China
| |
Collapse
|
47
|
Xia Y, Jin R, Peng L, Shou J, Wang J, Jin Y, Liang F, Zhao J, Wu M, Li Q, Zhang B, Wu X, Lan F, Xia L, Yan J, Shao Y, Stebbing J, Shen H, Li W. 1215P EGFR-mutated squamous cell lung cancer and its association with outcomes. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1820] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
48
|
Chen K, Kang G, Zhang Z, Lizaso A, Beck S, Lyskjær I, Chervova O, Li B, Shen H, Wang C, Li B, Zhao H, Chuai S, Yang F, Kanu N, Wang J. 1159P Individualized methylation-based dynamic analysis of cell-free DNA in postoperative monitoring of resected lung cancer. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1762] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
49
|
Hong X, Zhao J, Zhu X, Dai Q, Zhang H, Xuan Y, Yin J, Zhang Y, Yang X, Fang S, Wang Q, Shen H, Zhang Y, Yan D, Wang Y, Peng Z, Zhang Y, Wang B, Ma X. The association between the vaginal microenvironment and fecundability: a register-based cohort study among Chinese women. BJOG 2021; 129:43-51. [PMID: 34258836 DOI: 10.1111/1471-0528.16843] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2020] [Revised: 05/18/2021] [Accepted: 05/27/2021] [Indexed: 12/13/2022]
Abstract
OBJECTIVE To evaluate the association between the vaginal microenvironment and fecundability among women. DESIGN Register-based nationwide cohort study. SETTING Chinese National Free Pre-conception Check-up Project from 2015 to 2018. POPULATION Our study included a total of 3 388 554 eligible women who were attempting to become pregnant. METHOD We assessed the vaginal microenvironment at baseline by considering four indices: vaginal pH, clue cell examination, whiff test and vaginal cleanliness grading. If any of these indicators was abnormal, the vaginal microenvironment was defined as poor. Propensity score matching was used to control for potential confounders and reduce bias. Logistic models were used to estimate the fecundability odds ratios (FORs) after adjustment for covariates. MAIN OUTCOME MEASURES Achievement of a pregnancy within 1 year. RESULTS Of the total study population, 379 718 women (11.2%) had a poor vaginal microenvironment and their pregnancy rate after 1 year was significantly lower than the group with a normal microenvironment (71.8% versus 76.1%, P < 0.001). After adjusting for potential confounders, the women with a poor vaginal microenvironment were associated with a 9% reduction in fecundability compared with the normal microenvironment group (FOR 0.91, 95% CI 0.90-0.92). The adverse effects of a poor vaginal microenvironment were stronger among multipara (FOR 0.89, 95% CI 0.87-0.90) or women with irregular menstruation (FOR 0.86, 95% CI 0.84-0.89). CONCLUSION There was a negative association between a poor vaginal microenvironment and the fecundability of women. These findings highlight the significance of assessing the vaginal microenvironment during pre-pregnancy health examinations. TWEETABLE ABSTRACT Women with a poor vaginal microenvironment were associated with a reduction in fecundability.
Collapse
Affiliation(s)
- X Hong
- Key Laboratory of Environmental Medicine and Engineering of Ministry of Education, Department of Epidemiology and Health Statistics, School of Public Health, Southeast University, Nanjing, Jiangsu, China
| | - J Zhao
- National Research Institute for Family Planning, Beijing, China.,National Human Genetic Resources Centre, Beijing, China
| | - X Zhu
- Key Laboratory of Environmental Medicine and Engineering of Ministry of Education, Department of Epidemiology and Health Statistics, School of Public Health, Southeast University, Nanjing, Jiangsu, China
| | - Q Dai
- National Research Institute for Family Planning, Beijing, China.,National Human Genetic Resources Centre, Beijing, China
| | - H Zhang
- National Research Institute for Family Planning, Beijing, China.,National Human Genetic Resources Centre, Beijing, China
| | - Y Xuan
- Key Laboratory of Environmental Medicine and Engineering of Ministry of Education, Department of Epidemiology and Health Statistics, School of Public Health, Southeast University, Nanjing, Jiangsu, China
| | - J Yin
- Key Laboratory of Environmental Medicine and Engineering of Ministry of Education, Department of Epidemiology and Health Statistics, School of Public Health, Southeast University, Nanjing, Jiangsu, China
| | - Yue Zhang
- National Research Institute for Family Planning, Beijing, China.,National Human Genetic Resources Centre, Beijing, China
| | - X Yang
- National Research Institute for Family Planning, Beijing, China.,National Human Genetic Resources Centre, Beijing, China
| | - S Fang
- The Mount Sinai Health System, New York, NY, USA
| | - Q Wang
- Department of Maternal and Child Health, National Health Commission of the People's Republic of China, Beijing, China
| | - H Shen
- Department of Maternal and Child Health, National Health Commission of the People's Republic of China, Beijing, China
| | - Yiping Zhang
- Department of Maternal and Child Health, National Health Commission of the People's Republic of China, Beijing, China
| | - D Yan
- Department of Maternal and Child Health, National Health Commission of the People's Republic of China, Beijing, China
| | - Y Wang
- National Research Institute for Family Planning, Beijing, China.,National Human Genetic Resources Centre, Beijing, China
| | - Z Peng
- National Research Institute for Family Planning, Beijing, China.,National Human Genetic Resources Centre, Beijing, China
| | - Ya Zhang
- National Research Institute for Family Planning, Beijing, China.,National Human Genetic Resources Centre, Beijing, China
| | - B Wang
- Key Laboratory of Environmental Medicine and Engineering of Ministry of Education, Department of Epidemiology and Health Statistics, School of Public Health, Southeast University, Nanjing, Jiangsu, China
| | - X Ma
- National Research Institute for Family Planning, Beijing, China.,National Human Genetic Resources Centre, Beijing, China
| |
Collapse
|
50
|
Liu YT, Nguyen T, Goel S, Kai M, Shen H, Yokoi K. Abstract 2810: Effect of clone dependent difference in the metastatic tumor microenvironment of 4T1 breast cancer on anti-PDL1 antibody delivery & therapeutic efficacy. Cancer Res 2021. [DOI: 10.1158/1538-7445.am2021-2810] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Heterogeneities in the response of tumors to immunotherapies have significantly limited clinical benefits. Understanding the specific driving forces behind the heterogeneities will facilitate a better understanding of therapeutic resistance. Research has revealed that tumors in patients and established cancer cell lines are composed of multiple clones. Therefore, we established single cell-derived clonal populations from parental, polyclonal 4T1 murine breast cancer cells. Our goal is to dissect these complexities and decipher mechanisms of tumor heterogeneities. We injected 4T1 parental, clone1, or clone 16 cells into the spleen to create multiple liver metastases. Tumor-bearing mice were treated with anti-PDL1 Ab or isotype control Ab, then the therapeutic effect on tumor size and survival were evaluated. In another set of mice, the window chamber was installed above the liver to image the tumors utilizing intravital microscopy. Also, fluorescently labeled anti-PDL1 Ab or control Ab was injected intravenously (iv) to image the accumulation of Ab into the individual tumor. Anti-PDL1 Ab therapy significantly inhibited clone 16 tumor growth and extended survival of the tumor-bearing mice compared to isotype control Ab. On the other hand, parental and clone 1 tumors did not respond to the anti-PDL1 Ab. Using IVM, we monitored individual tumor response to anti-PLD1 Ab for 7 days and correlated the response with the amount of fluorescently labeled anti-PDL1 Ab delivered to the tumor. The amount of iv injected anti-PDL1 Ab delivery was heterogeneous among the tumors originated from 4T1 parental cells. We found an inverse correlation between the amount of the Ab delivered to the tumor and tumor growth, indicating drug delivery dependent tumor response. Metastases originated from clone 16 cells accumulated more amount of the Ab with most tumors disappeared. While the amount of Ab delivered to clone 1 tumor was significantly lower than parental and clone 16 tumors, none of the clone 1 tumors responded. Thus, limited therapeutic efficacy can be attributed to the insufficient anti-PDL1 Ab delivery to the tumor. Immunohistochemical analysis of resected liver revealed that the expression of PDL1 in clone 16 tumors was significantly higher than parental and clone 1 tumor. On the other hand. The amount of immune cells (CD8 & F4/80) were slightly higher in clone 16 than parental and clone 1 tumors. Finally, we compared the amount of coagulation inside the tumor by imaging fibrinogen, which can reduce therapeutics delivery to tumors. Interestingly, the clone 1 tumor showed significantly more amount of coagulation. Evaluation of heterogeneity in PDL1 expression, tumor coagulation, and the immune microenvironment in the patient's tumor shall be considered for personalizing the therapy.
Citation Format: Yan Ting Liu, Thao Nguyen, Shreya Goel, Megumi Kai, Haifa Shen, Kenji Yokoi. Effect of clone dependent difference in the metastatic tumor microenvironment of 4T1 breast cancer on anti-PDL1 antibody delivery & therapeutic efficacy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 2810.
Collapse
Affiliation(s)
- Yan Ting Liu
- Houston Methodist Research Institute, Houston, TX
| | - Thao Nguyen
- Houston Methodist Research Institute, Houston, TX
| | - Shreya Goel
- Houston Methodist Research Institute, Houston, TX
| | - Megumi Kai
- Houston Methodist Research Institute, Houston, TX
| | - Haifa Shen
- Houston Methodist Research Institute, Houston, TX
| | - Kenji Yokoi
- Houston Methodist Research Institute, Houston, TX
| |
Collapse
|